Toxicological Findings in Fatal Road Traffic Accidents in Cape Town: A Pilot Study by Shongwe, Nondumiso Khetsiwe Ntombi
Toxicological Findings in Fatal Road Traffic 
Accidents in Cape Town: A Pilot Study 
By 
Nondumiso Khetsiwe Ntombi Shongwe 
SHNNON012 
SUBMITTED TO THE UNIVERSITY OF CAPE TOWN 
In partial fulfilment of the requirements for the degree 
MPhil (Biomedical Forensic Science) 
Faculty of Health Sciences 
UNIVERSITY OF CAPE TOWN 
 
 
 
 
 
Date of Submission: 11 February 2019 
Supervisor: Bronwen Davies  
Co-supervisor: Kathrina Auckloo 
Division of Forensic Medicine and Toxicology 
Department of Pathology 
Un
ive
rsi
ty 
of 
ap
e T
ow
n
  
 
 
 
 
 
 
 
The copyright of this thesis vests in the author. No 
quotation from it or information derived from it is to be 
published without full acknowledgement of the source. 
The thesis is to be used for private study or non-
commercial research purposes only. 
 
Published by the University of Cape Town (UCT) in terms 
of the non-exclusive license granted to UCT by the author. 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Toxicological Findings in Road Traffic Accidents 
ii 
DECLARATION 
I, NONDUMISO KHETSIWE NTOMBI SHONGWE, hereby declare that the work on which this 
dissertation/thesis is based is my original work (except where acknowledgements indicate 
otherwise) and that neither the whole work nor any part of it has been, is being, or is to be submitted 
for another degree in this or any other university. 
I empower the university to reproduce for the purpose of research either the whole or any portion 
of the contents in any manner whatsoever. 
Signature: ………………………………… 
Date: ……11 FEBRUARY 2019…………………… 
   
Toxicological Findings in Road Traffic Accidents   
  iii 
 
RESEARCH SUMMARY 
Introduction: Road traffic accidents (RTAs) and associated morbidity and mortality are a global 
public health burden. Literature reports on an association between drugs and/or alcohol 
intoxication and traffic collisions. In South Africa (SA), where drug use and abuse are prevalent, 
annual RTAs rates are higher than the average global burden. Toxicological analyses in cases of 
RTA fatalities are not performed routinely in SA (apart from alcohol analysis), thus understanding 
the burden of other drug impairment on road traffic deaths is limited.  
Aim: A prospective toxicological analysis was performed in a cohort of road traffic fatality cases 
(drivers, passengers, pedestrians, motorcyclists and cyclists) from Salt River Mortuary in Cape 
Town, SA. The objectives were to perform drug screening in these cases to preliminary investigate 
detected substances as well as to evaluate the demographics and circumstances of death of the 
aforementioned cases. 
Methods: A systematic review was first performed to investigate the prevalence of drugs in 
internationally reported RTA fatalities. 
For the prospective study, post-mortem specimens including blood, vitreous humor, urine and bile 
were collected from cases in which next-of-kin consent was obtained. All samples were analysed 
using liquid chromatography-quadrupole time-of -flight mass spectrometry (LC/QTOF-MS). 
Results: Thirty cases were analysed over 3 months, of which most were male, pedestrians and 
between the age group of 31-40 years. The most prevalent cause of death was multiple blunt force 
injuries to the body. Single vehicle crashes were predominant particularly among the pedestrians 
and motorcyclists whereas drivers were mostly involved in multiple vehicle crashes. Substances 
(other than ethanol) were detected in 90% (n=27) of the cases. A broad range of drug groups were 
detected, and the most prevalent specific legal substances were caffeine (66.7%) and nicotinamide 
(53.3%) and illegal substances were methaqualone (10.0%) and methamphetamine (6.67%). 
Multiple cases indicated the detection of impairing substances even if consumed therapeutically, 
such as codeine, chlorpheniramine, diphenhydramine and zopiclone.  
Discussion: This study was the first to the author’s knowledge to report on prospective 
toxicological findings in road traffic accident cases in Cape Town. Although this was a pilot study, 
the results were in line with findings from other international studies, together with findings of 
prominent abused drugs within Western Cape (e.g. methaqualone and methamphetamine). While 
this study made no inferences of drug intoxication to cause of death, it has set a basis for future 
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research in this topic and the development of a standardised protocol for the routine analyses of 
such cases in SA. 
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Chapter 1: Background 
 
Road traffic accidents (RTAs) are a global concern with an associated high public health burden. 
Road users are at the risk of injury and fatality based on multiple risk factors. This chapter 
introduces the road user and explains the risk factors which may predispose them to RTAs. In 
addition, it provides contextual information on the role of alcohol and drugs and their involvement 
in the injury and/or death of road users. 
1.1   Road Traffic Accidents: A Global Public Health Problem 
This section defines and discusses the road user, road traffic injuries and fatalities in which they 
may be involved and the extent in which RTAs are a global burden to public health systems. 
 
1.1.1   Road Users  
All road users worldwide are at risk of RTAs resulting in injury and/or death, affected by varying 
environmental, safety and individual risk factors. A road traffic crash or accident is a collision or 
incident, which may or may not lead to injury and/or death, in which at least one moving 
(motorised or non-motorised) vehicle makes contact with other road users or stationary objects in 
a public or private road [1]. A road user refers to an individual using motorised or non-motorised 
transport on any part of the road system [2]. Motorised transportation includes two-or-more 
wheeled motorised vehicles powered by a motor engine, whereas non-motorised transportation 
refers to a transport method that does not need a motor to generate energy (e.g. cycling) [3] (Table 
1.1).  
 
Table 1.1: Types of road users based on the method of transportation. 
Motorised Transport User Non-Motorised Transport  User 
· Two-wheeled vehicles  
(e.g. motorcycle, moped) 
Drivers  
Passengers  · Walking  
Pedestrians 
· Three-wheeled vehicles  
(e.g. scooter taxi) 
Drivers 
Passengers 
· Two-wheelers  
(e.g. bicycle) 
Cyclists 
· Four-wheeled vehicles  
(e.g. car) 
Drivers 
Passengers 
· Three-wheelers  
(e.g. Tricycle) 
Cyclists  
· Others  
(e.g. truck, lorry, bus) 
Drivers  
Passengers 
· Human- and animal-powered vehicles 
(HAPV)  
(e.g. animal-drawn carts)  
Drivers 
Passengers 
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Road users are classified into five groups, namely drivers, passengers, pedestrians, motorcyclists 
and cyclists [4]. The last three groups are considered to be especially vulnerable road users based 
on the degree of external protection (e.g. vehicle without a shell), task capability (e.g. limitations 
due to disability, social or cultural circumstances), and resilience (e.g. novice or elderly drivers). 
Vulnerable road users usually bear the greatest burden of injury in RTAs [5].  
 
1.1.2   Road Traffic Injuries 
Over 5 million individuals die every year as a result of injuries, which accounts for approximately 
10% of all deaths globally [6]. In 2012, approximately a quarter of these injury related deaths were 
attributed to road traffic injuries (RTIs); one of the three leading injury-related causes of death 
(Figure 1.1) [7]. Recognised as a major global public health concern  [8],  RTIs are defined as  
fatal or non-fatal injuries as a result of a traffic accident [1]. The World Health Organization 
(WHO) estimates about 20 to 50 million individuals are injured (or disabled) every year in road 
traffic crashes; the wide range due to variability of reporting or lack thereof [9].   
 
 
 
 
 
 
 
 
 
 
 
Strategies to prevent road traffic crashes and resulting injuries require concerted and multi-
disciplinary efforts for effective and sustainable solutions. Unsurprisingly, road traffic injuries 
greatly affect vulnerable road users, especially children and young adults [7]. This burden has 
become the principal global cause of injury (and death) among the youth aged 5 to 29 years old 
worldwide [10] , warranting the need for greater attention in the current child health agenda.  
Figure 1.1: Distribution of the causes of injury mortality worldwide, 2012 [6]. 
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1.1.3   Road Traffic Fatalities 
RTIs have other consequences which affect both the individuals involved and their families. Non-
fatal health consequences include injuries leading to chronic treatment and hospitalization, mental 
health issues and changes in behavioural practices. The most devastating consequence though, is, 
one which leads to death [11]. Road traffic fatality (RTF) is usually reported as such when an 
individual dies within 30 days of the traffic crash and the cause of death (COD) was directly related 
to the collision [1]. Fatal traffic crashes have increased to approximately 1.35 million a year 
accounting for 2.5% of all deaths and becoming the 8th leading COD for people of all ages, globally 
(Figure 1.2) [10]. Without new initiatives and increased efforts to reduce these accidents, the 
number of traffic deaths is expected to rise significantly right through to 2020 [12]. This is 
particularly the case in low and middle income countries (LMICs) where there is a higher variation 
and level of traffic mix (i.e. different modes of transport, motorised and non-motorised, that share 
the same road network) and poor separation of the vulnerable, non-motorised groups from the fast 
moving, motorised vehicles [13]. 
  
 
 
 
 
 
 
 
 
 
1.2   Risks of Road Traffic Crashes 
This section speaks to the risks that road users are exposed to and hones in on the human risk factor 
of driving impairment due to alcohol and drugs of use and abuse. 
 
 
A
. 
B
. 
Figure 1.2: Global burden of road traffic deaths. (A) The number of road traffic deaths in millions from 
2000 to 2016. (B) The leading causes of death for all ages in 2016 [9]. 
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1.2.1   Understanding the risks  
The risks in which road users are exposed to in road traffic are comprised into four major aspects: 
i) exposure- the need to travel and movement in different parts of a transport system by different 
road user groups, ii) crash involvement given a particular exposure, iii) crash severity and iv) post-
crash outcome (Table 1.2) [13]. 
Table 1.2: Risk factors for road traffic injury and mortality [11]. 
 
The risk of RTIs and/or death is clearly multifactorial. A major contributor to road traffic crash 
involvement is factors affecting the individual, of particular note is impairment by alcohol and/or 
recreational or medicinal drugs (Table 1.2) [14]. The use of impairing substances by drivers and 
pedestrians may affect cognitive function and judgement. This in turn influences both crash risk 
and crash consequence, while increasing crash risks for others on the road [15]. 
 
1.2.2   Implications of Alcohol 
Driving under the influence of alcohol has been reported to greatly increase the risk of being 
involved in  traffic accidents [16] and it has been shown that drivers who have consumed alcohol 
are at an increased risk than those with who have not [17]. Due to the potential of impairment, 
i) Exposure: ii)  Crash involvement: 
 
· Demographics 
· Socioeconomic factors 
· Use of land and planning of road layout which 
effects distances of trip and mode of transport 
· Variation and traffic mix of motorised vehicles 
with non-motorised users 
 
 
· Travelling at high or inappropriate speeds 
· Use of alcohol and recreational or medicinal 
drugs 
· Vehicle defects such as brakes or tires 
· Environmental factors affecting visibility of 
the road and other vehicles 
· Road defects such as road maintenance 
 
iii) Crash severity: iv) Post-crash injury: 
 
· Lack of seat belt and child restraint use 
· Helmets and protective gear not worn by two 
wheeled road users 
· Human tolerance factors 
· Use of alcohol and recreational or medicinal 
drugs 
· Crash protection for vehicle occupants and 
those outside vehicle 
 
 
· Fire caused by the collision 
· Delay in detecting crash 
· Presence/leakage of hazardous materials 
· Challenges in rescuing, extracting or 
evacuating vehicle (car, bus, coach) occupants 
· Lack of necessary pre-hospital care or delay in 
getting to a hospital 
· Lack of appropriate hospital care and treatment 
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alcohol was found to increase the risk of crash involvement, crash severity, and/or post-crash 
injury outcome by affecting the drivers’ choice of speed [13]. 
It is estimated that alcohol-related road fatalities comprise approximately between 5-35% (with a 
weighted average of 21.8%) of all RTFs globally [18, 19]. Any amount of alcohol in a driver’s 
system has been shown to impair their driving behaviour, and there is a rapid and exponential 
increase in risk for blood alcohol concentration (BAC) levels exceeding legal driving limits for the 
general driving population worldwide [20]. The risk of an alcohol influenced crash varies with 
drinking experience and age, and the crash rates of younger aged males (16-20 years) was at least 
3 times that of men aged 25 years and above at every BAC level [16].  
In many low-income countries, there is a lack of equipment and human resources to routinely 
monitor the alcohol levels in drivers even though legal limits exist [21] and this makes it somewhat 
of a challenge to perform studies in which data can be compared across countries to understand 
the full status of the situation on a global level. In addition, many alcohol-related road fatalities 
involving pedestrians and cyclists, may not be documented if not considered as ‘active 
participants’ due to the absence of a ‘legal limit’ for these road users. Moreover, data on ‘drink-
driving’ – driving a motor vehicle under the influence of alcohol – remains scarce in multiple 
countries. Such information is crucial in understanding the extent of this public health issue as well 
as to evaluate the impact of prevention efforts. 
 
1.2.3   Implications of Drugs of Abuse (other than Alcohol) 
Similar to alcohol, any other substance that affects the central nervous system (CNS) (e.g. 
medicinal and/or recreational drugs) as well as cognition, behaviour and motor control, can 
contribute to road traffic crashes [22]. Their effects, however, on driving impairment and road 
crash involvement are not yet well understood than those of alcohol [23]. Establishing the role of 
causation versus contribution of drug use to a crash is therefore challenging, especially if other 
risk factors are involved [24]. 
The primary reasons for such complexities include the following: (a) unlike alcohol, a lot of drugs 
do not exhibit a direct relationship between drug concentration in blood and level of impairment 
[25], (b) drivers with medical conditions may be safer driving having taken their medication that 
may otherwise impair others (for example, schizophrenic patients prescribed antipsychotic drugs) 
[26], (c) the differences in which individuals respond to particular drugs at different doses and 
administration routes [13], (d) the differing short and long term effects of certain drugs [27], and 
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(e) antagonistic or synergistic effects of different drugs used together (e.g. concomitant use of 
drugs and alcohol) [28].  
There is still limited global information on the extent and role of substance use in cases of 
‘drugged-driving’. These also rely on improving our understanding of the effects of drug use on 
driving capacity, especially poly-drug use. Poly-drug use increases the risk of traffic accidents 
greatly [29] and this issue of drug involvement in traffic accidents needs urgent attention. In 
addition to this, there is increased complexity in interpreting drug concentrations in biological 
samples obtained from deceased individuals, where post-mortem factors may alter their 
concentrations. Improving our understanding of the presence of drugs in cases of road traffic 
deaths as well as improving our interpretive capacities of understanding the role of these drugs in 
the death is essential moving forward. 
 
1.3 Conclusion 
A systematic review was conducted to provide greater insight into the information available 
globally on the role of toxicology in road traffic deaths and the reported prevalence of substances 
in RTFs. This spoke to the availability of this data in developing countries, such as South Africa 
(SA), and developed a framework for the prospective investigation into drugs detected in a 
deceased cohort at a metropolitan mortuary in Cape Town. 
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Chapter 2: Systematic Literature Review 
 
A Forensic Toxicology Perspective on the Prevalence of Drugs of Abuse 
in Fatal Road Traffic Accidents using a Systematic Literature Review 
 
2.1   Abstract 
Background: Involvement of drugs in road traffic accidents (RTAs) is an important, yet not well 
understood problem, which is associated with a high global morbidity and mortality. There is also 
limited information on this issue in the context of the forensic services case load to which RTAs 
contribute significantly. The aim of this review was thus to systematically investigate the global 
prevalence of drugs of use and abuse reported in fatal RTAs. 
Methods: The review was conducted according to PRISMA guidelines in which original articles 
were searched for in PubMed, Scopus, Web of Science and CINAHL. Grey literature sources 
included Google Scholar, WorldCat and ProQuest Dissertation databases. The reference lists were 
all hand searched and the data was extracted by one reviewer with quality checks by two other 
reviewers. The data was qualitatively summarised based on the outcomes. 
Results: Of the 431 eligible articles, 42 were included in the review of which most were of poor 
to fair quality based on the quality assessment. Studies originated primarily from Europe and the 
most common road user group investigated were drivers of motorised vehicles. Overall, the 
prevalent substances detected were alcohol, followed by cannabis, benzodiazepines, stimulants 
and opioids.  
Conclusions: Studies were largely reported from developed countries. Insightful information was 
provided on the drug prevalence in fatal RTAs and the need to intensify enforcement action on 
drugged driving. More research is needed to investigate drugs in the vulnerable road user groups 
as well as to increase efforts to alleviate the limited resources and research capacity in developing 
countries where fatal RTAs are a significant burden.  
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2.2   Introduction  
Fatal RTAs and collisions continue to be a common occurrence and are one of the leading cause 
of mortality worldwide [14]. Forensic science plays a prominent role in the case investigation of 
human deaths, especially in determining the cause and manner of death of road traffic collision 
victims [30]. As part of this investigation, forensic toxicology - which includes the ancillary 
analysis for alcohol and drugs (therapeutic or recreationally used) in biological specimens - is 
crucial in understanding the possible contribution of substance impairment to the road traffic death 
[30]. 
Medico-legal road traffic cases can contribute substantially to a forensic toxicology laboratory's 
workload, allowing for numerous retrospective studies and available data. Many have reported on 
the potential role of alcohol, drugs of use and abuse (e.g. cannabis) [31, 32] or specific drug classes 
(e.g. benzodiazepines and amphetamines) in RTAs [33, 34]. The involvement of alcohol on the 
possible impairment of the driver has been most highly studied and reported on [15], however the 
effects of illicit and prescribed drugs on road users has received much less attention [35] .  
Currently, there is a lack of systematic evidence on the prevalence of drugs (other than alcohol) in 
fatal RTAs worldwide. This review intends to add to the literature and fill in the knowledge gap 
by providing an understanding of the role, effects and extent of drug involvement in such fatalities 
in the global context. Furthermore, the review will highlight the practice of routine toxicological 
testing in RTFs and its role in potential surveillance, intervention and prevention strategies. 
  
2.3   Objectives  
This systematic review was directed by the following research question: “What is the prevalence 
of drugs of abuse in global road traffic fatalities?”. With the aim to investigate the global 
prevalence of substances (alcohol and other drugs) commonly detected in fatal RTAs, this 
literature review provides a descriptive and comparative study of toxicological findings in victims 
of RTFs with the objective to assess the use and extent of forensic toxicological analyses in road 
traffic case investigations.  
 
2.4   Methods  
This review was performed according to the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) statement guidelines [36]. 
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2.4.1 Criteria for Considering Studies 
2.4.1.1   Types of Studies 
The inclusion and exclusion criteria for eligible studies in this review were: 
Table 2.1: Inclusion and exclusion criteria for review articles. 
Inclusion Exclusion 
 
i. Conducted anywhere in the world i.e. no 
restriction with regards to the geographical 
distribution to obtain a global overview.  
ii. Studies which reported on the prevalence, 
incidence and/or presence of any drugs in ante- 
or post mortem samples submitted to forensic 
toxicology laboratories to assist in the 
determination of the contribution of substances 
and impairment to the fatal RTAs   
iii. Studies which presented quantitative prevalence 
information in the form of percentage or 
proportion.  
iv. No timeframe restriction was applied to include 
all potentially relevant research study on the 
topic.  
v. Cross-sectional study design, which was most 
appropriate to address the review question.  
vi. Research studies reported in any language were 
included to avoid language bias.  
vii. Studies where road users were of any population 
group and of all ages. 
 
i. Non-original primary research such as 
opinions, commentaries, perspectives, and 
correspondences. 
ii. Single case reports which would not be 
representative of road user populations. 
iii. Research studies specific to certain drug 
class(es) or drug compound(s) which would 
bias the evidence towards that specific 
drugs being investigated.   
 
 
2.4.1.2   Population Types 
The review included road-traffic deaths of all types of road users, namely; drivers of motor 
vehicles, passengers, pedestrians, bicyclists, and motorcyclists.  
 
2.4.1.3   Types of Outcome Measures 
The outcomes chosen were deemed most forensically valuable in assessing the involvement of 
drugs of abuse in RTFs. The primary outcomes were: (a) the death of the road users, and (b) the 
practice of conducting a forensic toxicology investigation in such deaths. Secondary outcomes 
include the detection and identification of drugs of use and abuse in RTFs. These included (c) the 
toxicological general screening of substances, (d) the quantification of detected substances, and 
(e) the reported prevalence count.   
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2.4.2   Search Methods for Identification of Studies 
2.4.2.1   Information Sources 
For the identification of relevant prevalence studies in the field, four databases (PubMed/Medline, 
Scopus, Web of Science and CINAHL) were comprehensively searched for publications from 
inception to the 16th August 2018. Similarly, WorldCat, Google Scholar and ProQuest 
Dissertations were searched as grey literature sources to minimise publication bias. The reference 
lists of retrieved studies were hand-searched to ensure no relevant articles were overlooked. 
Overall, the search screened from the earliest published and un-published articles, working papers, 
dissertations, reports and other grey literature documented. 
2.4.2.2   Search Strategy 
Based on the PICO (Population, Intervention, Comparison, Outcome) framework for evidence-
based research [37], the following keywords were defined: ‘road users’, ‘substances or drugs of 
abuse’, and ‘fatal road traffic accidents or road traffic fatalities.  These pre-defined keywords 
were used to develop a broad range of medical subject headings (MeSH) terms in order to ensure 
a comprehensive and extensive search. For each database, combinations of the keywords and 
MeSH terms were used for all searches (Appendix A and B). Titles and abstracts of all records 
identified were screened for all pre-defined keywords. No language or date restrictions were 
applied in all searches.  
 
2.4.3   Data Collection & Analysis 
2.4.3.1   Study Collection 
The publications and articles identified as a result of the search strategy were independently 
screened for eligibility by one review author (NS) and any uncertainty on eligibility was resolved 
through discussion with two other reviewers (KA and BD). Subsequently, the full text of the 
included screened studies were assessed using the inclusion and exclusion criteria by one review 
author (NS) and consensus on any uncertainties was reached following discussion with the other 
two reviewers (KA and BD).  
2.4.3.2   Data Extraction & Management 
The JBI Data Extraction Form for Prevalence and Incidence Studies (Appendix C), a standardised 
data extraction form [38] , was used as a template and adapted accordingly to accommodate for the 
outcomes associated with the review question. One reviewer (NS) independently collected the 
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following information from each included article: (i) name of author(s), (ii) title, (iii) year of 
publication, (iv) country, (v) study time period, (vi) aims & objectives,  (vii) research 
question/hypothesis, (viii) population of interest, (ix) sample size, (x) methods of toxicological 
analysis, (xi) statistical significance, (xii) measurement instruments, (xiii) outcome measures 
(prevalence), (xiv) demographics, (xv) limitations, and (xvii) ethical considerations. Consensus 
was achieved on any disagreements regarding extracted data among all three reviewers (NS, KA, 
BD). When a study did not describe any of the above information of interest the original author of 
the study was contacted to request the necessary information.  
2.4.3.3   Quality Assessment of Individual Studies  
A descriptive quality assessment of the included articles was conducted using the AXIS (Appraisal 
Tool for Cross-Sectional Studies) tool, a critical appraisal tool developed to assess the quality of 
cross-sectional studies across disciplines (Appendix D) [39]. The AXIS tool addressed the study 
design and reporting quality as well as the risk of bias in cross-sectional studies, hence aiding the 
inclusion of such study designs in the systematic review. The tool’s focus is largely on the 
presented methods and results and provide the opportunity for reviewers to assess each individual 
aspect of study design to give an overall assessment quality rating. The tool does not use a 
numerical scale to assess the overall quality of a study but rather, allows for more flexibility in 
considering the quality of reporting and the risk of bias when reviewers make judgements on the 
quality of the studies [39]. The perceived limitation on the degree of subjectivity in assessing the 
quality of the studies was mitigated by having three reviewers (NS, KA and BD) independently 
assess the quality of the included studies. Any disagreements were resolved by discussion to reach 
a consensus. 
 
2.5   Findings 
2.5.1   Search Result 
From the electronic databases and grey literature sources searched 639 publications were identified 
in total, of which 168 were duplicates. Therefore, 471 publications were screened for initial 
eligibility based on the title and abstract. Subsequently, 431 citations were excluded, narrowing 
the number of articles eligible for full-text review to 40 (Figure 2.1). Upon assessing the reference 
lists of reviewed articles, an additional 11 articles were identified. Out of the total 51 potential 
studies, 9 were excluded and 42 studies (Appendix E) were included in this review’s quantitative 
analysis. 
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2.5.2   Quality Assessment 
As shown in Table 2.2, most of the included studies were of fair or poor quality, with less than a 
third deemed to be of good quality.  
Table 2.2: Quality assessment of included articles. 
Quality 
Rating 
Main Features 
Number of 
articles (%) 
Citations 
Good 
Methods were sound and applicable and clear results were 
provided in relation to the aim of the study. 
11 (26.2) [40-50] 
Fair 
Insufficient description of the methods provided but adequate 
description of the results which were internally consistent. 
16 (38.1) [51-66] 
Poor 
Older studies which lacked sufficient descriptions of the methods 
as well as descriptions of basic descriptive data in the results. 
15 (35.7) [67-81] 
 
 
Figure 2.1: Flow diagram illustrating the literature search strategy. 
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2.5.3   Global Distribution  
The included studies originated from 6 continents, with most coming from Europe (45.2%), and 
North America (28.6%) (Table 2.3). Most of the studies from the same country (e.g. Norway, 
Sweden and the United States) collected data from the same database but during different study 
periods, covering different years and in some instances focusing on different states, counties or 
type of road user.  
 
Table 2.3: Global distribution of included articles. 
Continents 
Total number of 
studies (%) 
Countries (number of studies) Citations 
Asia 4 (9.5%) 
Jordan (2) 
Iran (1) 
Hong Kong (1) 
[53, 54] 
[67] 
[56] 
Australia 1 (2.3 %) Australia [82] 
Europe 19 (45.2 %) 
Norway (4) 
Sweden (4) 
United Kingdom (3) 
Spain (2) 
Slovakia (1) 
Czech Republic (1) 
Portugal (1) 
Scotland (1) 
Nor, Swe, Port, Fin (2) 
[40, 43, 58, 59] 
[51, 52, 61, 74] 
[57, 78, 83] 
[42, 84] 
[77] 
[77] 
[70] 
[60] 
[45, 46] 
North America 16 (38.1 %) 
United States (12) 
Canada (4) 
[41, 48-50, 65, 68, 
71-73, 75, 80, 81] 
[62, 66, 69, 79] 
Oceania 1 (2.3 %) New Zealand [47] 
South America 1 (2.3 %) Brazil [64] 
 
2.5.4   Study Timeline 
The year of publication (Figure 2.2) and study duration (Figure 2.3) for all included studies were 
wide and varied. The earliest article was published in 1974 in the United States [81] and the most 
recent in 2017, in Scotland [60], while the shortest and longest study periods were 10 months [68] 
and 18 years [70], respectively. The overall average study period was 3.8 years.  
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2.5.5   Study Population 
Road users involved in fatal RTAs were the population of interest in all 42 included studies. 
However, the most prominent subgroup under investigation were drivers (28 articles -66.7%) of 
motorised vehicles [40-42, 45-52, 56, 58, 59, 61, 62, 66-68, 71, 74, 75, 79-84]. As shown in Figure 
2.4, only 5 (11%) studies comprehensively looked at all road users simultaneously i.e. drivers, 
passengers, pedestrians, motorcyclists, and cyclists [57, 63-65, 77].  
Only 32 studies reported on distribution of the victims’ sex, with male fatalities being more 
prevalent in the samples investigated. The mean number of males investigated in these studies was 
1734 whereas that of females (only reported in 31 studies) was 503.  The age of the victims 
reported in all the 42 studies were varied, ranging from as young as 17 years to as old as 80 years. 
For most studies, the highest drug prevalence was in individuals aged between 20 to 40 years old.  
 
 
 
 
 
 
 
 
 
 
 
 
 
2.5.6    Measurement of Outcome Variables (in the individual studies) 
Of all included studies, prevalence of drugs detected was the major outcome variable measured 
(n=32) with half of these articles lacking significant statistical analyses such as Chi-Square tests 
and p-value reporting. Of the articles reporting statistical prevalence, 14 performed Pearson’s Chi 
Square test, and 9 reported p -values in relation to the prevalence of substances detected [42, 43, 
46, 50, 52, 59, 61, 63, 77].  Incidence was the next important measurement of outcome variable 
Figure 2.4: The proportions of the different road user group studied across the included 
articles. 
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(n=6) with all but one study lacking any statistics. The remaining articles reported prevalence ratios 
with statistical analyses reported as either p-values and/or 95% confidence intervals. These 
statistical analyses were not in relation to the prevalence of drugs detected but rather on the sample 
demographic variables or crash characteristics (single vehicle crash or multiple vehicle crash). 
 
2.6   Outcome Measures  
2.6.1   Drug Screening Methods  
All included studies conducted a broad drug screening for licit and illicit substances, except for 
one study which screened for drugs other than alcohol [77]. Qualitative analyses were also 
performed in 16 studies where six  only screened for substances [45, 46, 52, 53, 64, 67]. These 
studies only used one technique, whereas ten performed screening and confirmatory analyses [42, 
54, 57, 60, 61, 63, 65, 68, 75, 78] by employing two or more different techniques for confirmation. 
Quantitative analyses (screening and quantification) were also performed 16 studies [40, 43, 44, 
47, 50, 55, 56, 58, 59, 66, 69, 71, 73, 74, 76, 80]. There were 10 studies [41, 48, 49, 51, 62, 70, 72, 
77, 79, 81] which had no toxicology analysis details.  
Various techniques were used in these studies. The most common technique used for these 
toxicological analyses was gas chromatography mass spectrometry (GC-MS) (n=32). Headspace 
GC or GC-flame ionisation detection (GC-FID) were used predominately for alcohol analyses. 
Immunological assays, GC-MS and/or liquid chromatography mass spectrometry (LC-MS), 
tandem mass spectrometry (LC-MS/MS) and high performance liquid chromatography mass 
spectrometry (HPLC-MS) were used in 20 studies [40, 42, 50, 52, 56-61, 63, 65, 66, 68, 72, 74, 
75, 78, 83, 84]. Ultraviolet spectrophotometry (UVS) [73] as well as thin layer chromatography 
(TLC) [81], were reported in single studies respectively. Other techniques are mentioned in Table 
2.4. 
 
2.6.2   Prevalence of Alcohol and Drugs 
Reporting of the prevalence of alcohol and drugs varied in the studies in that some recorded the 
overall prevalence whereas others reported on the prevalence of the specific drugs/drug classes 
detected. The overall prevalence for both alcohol and drugs was reported in 25 studies [42, 43, 45, 
46, 50-52, 58, 59, 62-65, 68-70, 72-75, 78, 80-82, 84].  On the other hand, seven  studies reported 
alcohol only [40, 41, 47, 48, 53, 60, 71], two reported drugs only [49, 79] and eight studies did not 
report the overall prevalence for either alcohol or drugs in their populations [54, 56, 57, 61, 66, 67, 
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77, 83]. Instead, they reported on the prevalence of specific drugs/drug classes detected either in 
combination with alcohol or alone.  
The most prevalent drugs detected in the studies were reported and these varied widely. Alcohol, 
however, was reported as the most commonly detected substance in 41 studies. The most prevalent 
drugs classes after alcohol were cannabinoids (cannabis), benzodiazepines, stimulants and opioids 
(Table 2.4). The common specific compounds within the first 3 classes were tetrahydrocannabinol 
(THC) and its metabolites, diazepam and amphetamine respectively. 
Table 2.4 shows the overall reported alcohol and drug prevalence for studies from 17 countries. 
These were recorded as ranges for multiple studies originating from the same country. The samples 
tested, techniques used, analysis performed, most common drug classes and the specific 
compounds reported are illustrated. 
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Country 
Overall 
alcohol 
prevalence 
(range) 
Overall drug 
prevalence 
(range) 
Sample(s) Techniques Analysis Drug classes Specific drugs 
Australia 29.1% 26.7% Blood None mentioned 
Screen and 
confirmation 
Benzodiazepines                                                                                                                                                                                                                                                                                                                                                      
Opioids                                                                                                                                                                                                                                                                                                                                         
Stimulants 
Brazil 36.1% 17.9% Blood 
Head space GC-FID                                                                                                                                                                                                                                                                                                                                
GC ion trap MS 
Screen 
Cannabis
Stimulants                                                                                                                                                                                                                                                                                                                                                                            
- 
Amphetamine, cocaine   
Canada 48.1-57.0% 4-26% 
Blood, urine, 
vitreous humor 
(VH) 
Immunoassay, head 
space GC-FID, GC-
MS, LC-MS/MS 
Screen and 
confirmation 
Antidepressants  
Benzodiazepines  
Cannabis  
Opioids       
- 
-                
Diazepam 
Tetrahydrocannabinol (THC) and carboxy THC 
- 
Salicylate 
Czech 
Republic 
34.7% 7.2% Blood 
Immunoassay (specific 
analytic techniques not 
mentioned) 
Screen and 
confirmation 
Benzodiazepines                                                                                                                                                                                                                                                                                                                              
Cannabis                                                                                                                                                                                                                                                                                                                                                   
Stimulants  
Hong Kong - - Blood, urine 
Immunoassay, GC-
FID, GC-MS or LC-
MS, GC-NPDa, HPLC-
DADb 
Screen and 
confirmation 
Stimulants  
Cannabis 
Benzodiazepines  
Dissociative anaesthetics 
Methylenedioxymethamphetamine (MDMA) 
- 
- 
Ketamine 
Iran - - 
Blood, VH, 
tissue 
GC, HPLC Screen Opiates  
Jordan 37.1% - 
Blood, urine, 
VH 
GC-FID, GC-MS                                                                                                                                                                                                                                                                                                                                                                                   
Screen and 
confirmation 
Anti-depressants 
Barbiturates  
Benzodiazepines  
Opioids 
 
New 
Zealand 
34.0% - Blood 
Immunoassay, GC-MS, 
GC-NPD, LC-MS-MS 
Screen and 
confirmation 
Stimulants                                                                                                                                                                                                                                                         
Benzodiazepine                                                                                                                                                                                                                                                                                                               
Opioid  
Methamphetamine
Diazepam 
Methadone 
Norway 25-44.6% 15.3-16.4% Blood 
Immunoassay, GC-MS, 
HPLC, GC-MS/LC-MS                                                                                                                                                                                                      
Screen and 
confirmation
Benzodiazepines  
Cannabis  
Benzodiazepines 
Stimulants
                         
- 
Diazepam 
THC  
- 
Amphetamines, cocaine, methamphetamine,
MDMA 
Methadone   
Portugal 55.0% - Blood GC-FID, GC-MS Screen 
Opiates  
Cannabinoids  
 
Scotland 24.0% - Blood 
Immunoassay, GC-
FID, GC-MS or LC-
MS/MS                                                                                                                                                                                                                                                                                  
Screen and 
confirmation 
Benzodiazepines                                                                                                                                                                                                                                                                                                                                                           
Cannabinoids                                                                                                                                                                                                                                                                                                                                     
Opioids                                                   
 
Table 2.4: Samples, techniques and overall drug and alcohol prevalence per country. 
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Slovakia N/A - Retrospective study 
Benzodiazepines                                                                                                                                                                                                                                                                                                                                             
Cannabis 
 
Spain 32-50.5% 9.1-63.7% Blood 
Immunoassay, head 
space GC-MS, GC-MS, 
HPLC 
Screen and 
confirmation 
Anti-depressants  
Analgesics  
Benzodiazepines 
Cannabis 
Designer drugs 
Opiates 
Stimulants  
 
Sweden 21-67% 7-10% 
Blood, urine, 
VH 
Immunoassay, head 
space GC-MS, GC-MS, 
LC-MS 
Screen and 
confirmation 
Analgesic  
Anti-depressant  
Benzodiazepines  
Cannabis  
Sedative hypnotic (Z-drugs) 
Opiates 
Stimulants  
- 
- 
Paracetamol 
Citalopram 
Diazepam, flunitrazepam 
THC 
Zopiclone 
- 
Amphetamine, cocaine, MDMA 
GHBc 
Tramadol 
UK 36.0% 7.4% Blood, urine 
Immunoassay, GC–
FID, GC–NPD, GC–
MS, HPLC–DAD 
Screen and 
confirmation 
Anticonvulsant                                                                                                                                                                                                                                                                                                                                                
Antihistamines 
Benzodiazepines  
Cannabis                                                                                                                                                                                                                                                                                                                                 
 
US 13-70% 5-81% 
Blood, urine, 
VH, bile 
Imunoassay, head 
space GC, GC-MS, 
GC-NPD, GC-FID, 
HPLC, UVS, TLC 
Screen and 
confirmation 
Barbiturates  
Benzodiazepines                                                                                                                                                                                                                                                                                              
CNS Depressants                                                                                                                                                                                                                                                                                                                                   
Cannabis                                                                                                                                                                                                                                                                                                                           
Stimulants  
Narcotic analgesics   
Sedative hypnotic                                                                                                                                        
Sympathomimetic drug  
-                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
Phenobarbital  
Diazepam
-
Cocaine, amphetamines, methamphetamine
Morphine/Codeine, Propoxyphene     
Methaqualone    
Penylpropanolamine, ephedrine,
pseudoephedrine 
Phencyclidine                                                                        
Fin, Nor, 
Swe, Port 
42-44.9% 31-48% Blood 
Head space GC, HPLC/ 
UPLCd, GC MS-
MS/NPD 
Screen and 
confirmation 
Benzodiazepines 
Cannabis 
Stimulants  
- 
THC 
Amphetamine 
a. GC-NPD: Gas Chromatography – Nitrogen Phosphorous Detector 
b. HPLC- DAD: High-Performance Liquid Chromatography with Diode-Array Detection 
c- GHB: Gammahydroxybuturate 
d- UPLC: Ultra Performance Liquid Chromatography 
The information in this table has been grouped together from the studies to illustrate alcohol and drug prevalence per country. Where there were multiple studies originating 
from one country, the prevalence was expressed as a range and single studies have one value (except the UK- only one study reported overall prevalence for alcohol and 
drugs). In some studies, only drug classes were reported without mention of the specific drugs within that class and in other instances, the specific drugs were reported and 
not classified into drug classes. 
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2.6.3   Extent of routine toxicological analysis in fatal RTAs 
Routine toxicological analysis was not explicitly reported in all the studies and some studies within 
same country reported different information regarding the routine testing. There were ten  studies 
in which there was no mention on routine testing [42, 45, 46, 51, 59, 66, 69, 70, 79, 84], twelve   
in which routine toxicology was alluded to [40, 49, 52, 57, 58, 60, 61, 67, 70, 74, 82, 83], eleven  
in which routine toxicology was reportedly not performed [43, 53, 54, 56, 62-64, 77, 78, 80, 81] 
and nine in which the testing was said to be inconsistent between the states [41, 48, 50, 65, 68, 71-
73, 75] .  
 
2.7   Discussion 
2.7.1   Quality of articles 
The number of articles present on this specific question are very few considering how large the 
global burden of RTFs is, and the acknowledgement that alcohol and drugs are major risk factors 
to traffic deaths. Following the review, most of the articles were deemed to be of medium to poor 
quality. There is a need to reiterate the importance of good quality research for this topic. It is 
understood however, that post-mortem research is extremely difficult due to the nature of the work 
as well as medico-legal and ethical requirements. Analyses regarding quality assessment were not 
performed here due to time restrictions. However, a meta-analysis to quantitively compare the 
prevalence data according to the study quality will be conducted. 
 
2.7.2   Study Characteristics 
Most of the studies originated from developed countries and only one each from Brazil, Iran and 
Jordan, which are considered developing countries. Six out of the seven continents were 
represented by the studies with most originating from European and North American populations 
respectively. No studies originated from Africa. This is quite interesting as it has been reported 
that, although RTFs are a global burden, most are contributed by low-middle income countries 
[85] most of which are in Africa. There have been studies published regarding RTAs and drug use 
separately and the effects they have on public health and the economy [86, 87]; however, the lack 
of resources and slow growth of forensic toxicology capacity in these countries is most likely the 
reason for the scarcity of literature on the specific topic of this review [88].  The years of 
publication for most of these studies (31%) were between 2010-2015 which are more recent years. 
This is most likely due to the acknowledged burden of fatal RTAs caused by impairment as well 
as effort towards understanding the role and involvement of drugs in these fatal RTAs. 
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2.7.3   Demographics 
The population demographics reported indicated that males made up the dominant proportion of 
fatally injured road users in which drugs were detected. The age group mostly affected was 20-40 
years old. These are young, working class individuals who are meant to be contributing to the 
economy of the countries [89]. It may be suggested that this burden is generating  economic 
adversity due to the loss of family breadwinners [90]. 
The most studied road user group was drivers of motorised vehicles. This might be due to the fact 
this is a highly monitored victim group [57] and so most the data available is predominantly based 
on this group. In general, there are likely also more drivers than other road users in certain countries 
from which this data was reported. Very few studies investigated the presence of drugs in all road 
user groups and yet what has been reported in other literature, particularly from a global 
perspective, is the most vulnerable road user groups are pedestrians, cyclists and motorcyclists 
[91]. More research and monitoring of routine toxicological data from these cases, is necessary to 
get further insight into drug use and its contribution to fatal RTA by these vulnerable road user 
groups. 
2.7.4   Substance analyses 
An equal number of articles reported on having performed qualitative and quantitative toxicology 
analyses. For those reporting on the latter, quantification was done mostly for alcohol to determine 
the number of decedents who had BAC above the legal limits for the respective countries. The 
main specimen used in these studies was blood, followed by urine. Although post-mortem vitreous 
humor and post-mortem urine alcohol concentrations are obtained and can usually be interpreted 
to indicate previous ethanol administration, blood alcohol concentration is most often obtained for 
interpretive value and the standard technique is head space GC-FID [92]. Only a few of the studies 
quantified drugs other than alcohol. The effects of alcohol impairment in relation to BAC has been 
extensively studied [61, 70] and so specific legal limits for BAC in drivers have been defined in 
road traffic legislation. This is typically not the case for other drugs.  
There are many challenges when it comes to interpretation of drug concentrations in biological 
samples, especially post-mortem samples. The specimens used for drug screening need 
consideration regarding the complexity of the sample, the technique to be used as well as expected 
results. For example, urine is simpler specimen compared to blood or VH, however, detection of 
substances in urine is only indicative of exposure. Quantification may not offer valuable 
information since concentrations are generally higher in this specimen and do not correlate to 
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blood levels or toxic effects [93]. Relating concentrations of drug to levels of impairment is 
complex and often not possible in a post-mortem context [63]. A phenomenon known as post 
mortem re-distribution, in which drug concentrations alter after death contribute to this uncertainty 
in determining the role of a drug in the victim of a fatal RTA [50, 52, 84]. In addition, both autolysis 
and putrefaction, which are decomposition processes may increase or decrease the levels of drugs 
in post mortem specimens [94]. The chemical stability of the drugs is also a factor to be considered 
particularly with highly volatile substances which may break down rapidly after death [95]. 
Furthermore, storage of samples may also affect the stability of drugs present where improperly 
stored samples or long storage periods may result in degradation of drug compounds [96]. The 
interpretations of drug post-mortem concentrations and their relation to impairment at the time of 
the collision, must always be done with caution, and with consideration of individual and 
circumstantial factors. 
2.7.5   Prevalence of substances 
The most prevalent licit substance detected in these studies was alcohol. This finding is of no 
surprise and is in keeping with numerous studies that have reported a high association of alcohol 
impairment in RTAs [97-100]. Driving under the influence (DUI) of alcohol exponentially 
increases the risk of serious accident or death [101]. Even with small amounts of alcohol 
consumption, drivers are twice as likely to be involved in an accident than sober drivers [102] and 
poly drug use, particularly with alcohol pose an even greater risk of being involved in a traffic 
accident [29]. Although there have been efforts worldwide to reduce drink driving through 
publicity, education and tough drink driving laws and penalties, drunk driving is still a significant 
global public health burden [103]. 
The most prevalent non-alcoholic drugs were cannabis, benzodiazepines, stimulants and opioids, 
many of which are common global drugs of abuse [104, 105] and have been observed as 
contributors to impairment while driving. The most prevalent specific drugs in those drug classes 
were THC, diazepam and amphetamines. A point worth mentioning is that, some studies only 
screened for drugs, i.e used one technique to detect substances in the specimens. The technique 
used for screening is important because some techniques are not sensitive enough to distinguish 
between drug classes, let alone detect specific drugs [106]. This is the case with immunoassays, in 
which a lot of studies used this technique for screening. As such, it is recommended that 
confirmatory tests be performed with a different, more specific technique to allow for 
unambiguous detection [107]. Another point worth mentioning is targeted versus non-targeted 
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screening. The former is screening for specific drugs whereas the latter is a broad-spectrum screen 
for presence of any drugs. The strategy chosen, will have a bearing on the drugs detected and the 
prevalence thereof. Although this was not mentioned explicitly in the studies, it is an aspect to 
keep in mind in the interpretation of the results regarding drug prevalence. 
2.7.6   Routine toxicological analysis 
The extent of routine toxicological analysis for fatal RTAs was not easy to determine as not all the 
studies explicitly mentioned or discussed this aspect. This was assessed by the reviewer based on 
the information in the methods and discussion sections of the studies. In addition, in some studies 
from the same countries, information regarding routine testing was different and so this made it 
difficult to determine which countries might routinely perform toxicological analyses. A possible 
explanation for the seemingly contradictory information is that different areas within the same 
country are serviced by different laboratories which may or may not have the capacity to perform 
toxicological analyses.  However, what was noted from the studies was the valuable information 
provided by these analyses which would aid in the development of drug use management and 
interventions [77]. It’s important to note that there are no universal legislative / laboratory 
requirements with regards to forensic toxicological testing in these cases. There are some countries 
which have employed different approaches, namely; i) identification of signs of impairment, ii) 
identification of drugs in biological specimens above a specific or cut off concentration (per se 
limits) or zero tolerance if per se limits have not been determined and iii) mixed systems combining 
the both impairment identification and per se limits  [108]. There are however, recommendations 
made by Logan et al. [109] on the drugs which should be screened for in such cases. These 
recommendations were written in an effort to standardise toxicological analyses in such cases and 
are therefore, a good starting point as guidelines for countries to implement routine toxicological 
testing. 
 
2.7.7   Limitations 
The most notable limitations in the included studies were selection bias and non-responder bias. 
Most of the studies focused on the driver user group only. A small number of studies actually had 
all user groups as part of their study sample. In addition to that, most of the studies had a low 
response rate where most of the loss of cases was due to mainly: (i) lack of adequate case 
information leading to exclusion based on the criteria, (ii) insufficient samples for drug analyses 
and (iii) inappropriate or no samples collected for testing.  Studying only one group of the road 
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user population and the high loss of eligible cases is not representative of the road user population 
and potentially leads to bias in the data where there might be an under or over representation in 
the estimates reported [41, 43, 58, 70, 82].  
Another limitation of the studies in general was is a lack of global consistency in toxicological 
analyses and reporting. Because of this, there is bias in the results- for example, the studies which 
screened only urine for drugs would identify more drugs than those that screened blood. Likewise, 
studies which performed a targeted screen may identify fewer drugs than a non-targeted screen. 
Another point of consideration is that the limits of detection and quantitation of analytes vary 
according to sensitivity of instruments. Collection procedures and sample storage could also result 
in biased findings.  
Additionally, neither of the studies had control groups (non-fatal DUI of drugs cases) in which to 
compare their findings. This comparison would provide better information of drug trends and the 
prevalence thereof. The role of these drugs in death was also not assessed as this is a complex and 
multi-factorial process often requiring case specific evaluation and determination.  
The limitations of this review itself is the potential reviewer bias as the reviewer independently 
screened the articles and extracted the data with only a 7% random check by two other reviewers. 
Secondly, this review was based on reports from higher-income countries and none from lower 
income countries as none were available or fit inclusion criteria. This potential bias was addressed 
as best as possible through extensive searching of grey literature for unpublished material, reports 
and conference papers. Lastly, the exclusion of eligible articles due to lack of access to the full 
texts. An email was sent to the relevant authors but, unfortunately, there has been no response to 
date. 
2.8   Conclusion 
Studies investigating the prevalence of substances in road users of fatal RTAs originated mostly 
from developed countries, which typically have the resources and capacity to carry out such 
research and routine services. This has provided meaningful information and has highlighted that 
alcohol, cannabis, stimulants, benzodiazepines and opioids are more so reportedly involved in fatal 
RTAs and there remains a clear need to intensify strategies to prevent drunken and drugged 
driving. The challenges regarding drug use and traffic accidents are complex and multifaceted, and 
more research is necessary to understand and purport the role of drugs and their concentrations in 
post-mortem samples to causing and contributing to fatal RTAs.  
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This review also highlighted a gap in the literature regarding drug use in the lesser studied 
vulnerable road user groups. Further, research and routine reporting is needed to gain a more in-
depth insight into the involvement of drugs in these vulnerable groups. Although routine 
toxicological testing for fatal RTAs was not highly evident in this review, what was noted was 
toxicological analyses in these fatal RTA cases provide insightful information regarding the trends 
of drugs and alcohol in victims of fatal road collisions.  
Developing research and routine toxicological service capacity within LMICs is necessary to 
investigate these trends further in countries seen as providing a higher burden of RTFs. Developing 
consistency in testing and reporting on a national and international level, would be worth striving 
towards to better understand this burden as a whole.  
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Chapter 3: Toxicological Findings in Fatal Road 
Traffic Accidents in Cape Town: Introduction 
 
Chapter 1 highlighted the global burden experienced due to RTFs and the risk factors that 
contribute to these fatalities. The particular risk factor focused on was driving impairment due to 
presence of alcohol and drugs of use and abuse. The prevalence of substances in global RTF was 
investigated systematically in Chapter 2, which included evaluation of the role and extent of 
toxicological analyses used in these fatalities.  
It was necessary to compare the findings outlined in Chapter 2 to a local context within SA. The 
following chapters discuss traffic deaths in Africa, with a focus on Cape Town, Western Cape, 
where the prospective study was performed. Insight into the drugs of abuse in SA is also provided 
to contextualise the study rationale. 
 
3.1 Distribution of Road Traffic Deaths 
3.1.1 Distribution as per WHO’s world group regions 
Geographical differences in road traffic death rates exist both across the six WHO regions (Figure 
3.1) and within those regions themselves [13, 110]. Countries in Africa and South-East Asia report 
traffic death rates much higher than the global rate and the developed Europe and Americas regions 
(Figure 3.1) [110]. 
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3.1.2 Distribution as per country income classifications 
LMICs produce approximately 90% of the global road traffic deaths, accompanied by increased 
urbanization and an increased number of vehicles on the road [85]. LMICs in the Africa region 
have reported rates of 23.6 per 100 000 and 29.3 per 100,000 population, respectively [110]. RTAs 
affect vulnerable road users i.e. cyclists and pedestrians [91], which is particularly the case in 
LMICs where these groups are highly inter-mixed on the roads [13]. Contrary to LMICs, there has 
been a decrease in the rates of RTA fatalities over time in high income countries (HICs), but still, 
the global economic costs is rising substantially [111]. A global estimate of US $518 billion 
annually is lost due to RTAs in the form of emergency services costs, medical costs, legal and 
court cost, lost productivity, property/motor vehicle damages, workplaces loss, insurance 
administrations [112] . LMICs account for an estimated US $65 billion, which is more than these 
countries usually receive in financial support [113, 114]. These observations illustrate the fact that 
LMICs carry a large portion of the burden of the world’s road traffic deaths. 
 
3.2 The Burden of Road Traffic Deaths in South Africa  
With LMICs in Africa contributing the highest rates of global road traffic morbidity and mortality, 
a closer look at the traffic death rate in SA is necessary to gain insight into the local context. 
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 Figure 3.1: Rates of road traffic death per 100,000 population by WHO-defined regions, 
2016 [2].   
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In 2007, road traffic injuries in SA were ranked second highest after interpersonal violence causing 
death [115].  In 2017, 14 050 RTFs were reported, with pedestrians and passengers being most 
affected (Figure 3.2) [116].  Half of the deaths affected people aged between 20-44 years in all 
road user groups [117, 118].  In 2015, the cost of RTAs was reported to be R142.95 billion, 
approximately 3.4% of the country’s gross domestic product (GDP), whereas in other similar 
countries, the average cost was 2.2% of their GDP [119, 120]. 
 
 
 
 
 
 
 
 
 
 
 
 
The traffic fatality rate of SA in 2016 was 25.9 per 100 000 [110], one of the highest rates in  the 
Africa region.  Based on the Road Traffic Management Corporation’s (RTMC) 2017 report, four 
out of the nine provinces in SA – Gauteng (GA), Kwazulu Natal (KZN), North West (NW) and 
Western Cape (WC) have achieved greater fatality reductions than the other five provinces [116]. 
Although there has been a reduction in traffic fatalities in the WC province, the fatality rate of 
Cape Town is 30 per 100 000 [121] which is higher than that of Africa region itself. 
 
3.3 Drugs of Abuse in South Africa  
The information available on the extent of drug use and drug-related deaths in LMICs is lacking 
due to the limited resources and expertise to evaluate the issue [122]. SA is no exception to this. 
Figure 3.2: Percentage distribution of fatalities per road user group in 2017 in 
SA [9].  
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Although there exists an alcohol or drug (AOD) surveillance system known as South African 
Community Epidemiological Network on Drug Use (SACENDU), the data is based on reports of 
patients admitted into AOD treatment facilities [123] and is therefore not representative of the 
general population. Thus, determining the prevalence of drug use in SA is challenging due to the 
lack of recent nationwide drug use surveys [124]. Toxicological analyses in all unnatural deaths is 
also not performed routinely, thus monitoring the drugs present in the deceased populations in SA 
is not currently feasible. 
Information gathered from the limited research suggests that alcohol is the most widely abused 
substance [125] with cannabis, methamphetamine, heroin and cocaine being the main illicit drugs 
of abuse in SA [126, 127]. Cape Town, the capital city of Western Cape province has been noted 
as having high levels of drug abuse and drug related problems [123]. There is a continual increased 
use of methamphetamine, locally known as “tik,” which has become the major drug of abuse in 
the province, [128] followed by cannabis [129] and methaqualone (“mandrax”).  
While cognitive, motor and behavioral impairment associated with psychoactive drug use is 
recognised, there is currently a lack of research in SA investigating the prevalence and role of 
drugs in RTA fatalities. 
 
3.4 The South African Medicolegal System 
In SA, the Inquest Act (Act 58 of 1959) provides for procedures to be followed in cases of death 
which are due to unnatural causes (i.e. suicide, homicide, procedure-related and accidents) [130]. 
Certified Forensic pathologists in provincial Forensic Pathology Services (FPS), perform post-
mortem examinations on suspected unnatural cases to determine the COD. The manner of death 
(e.g. suicide, homicide, accident) is usually determined by the Court during inquest or criminal 
proceedings. At the time of performing the autopsy, pathologists will assess the need to request 
drug and/or alcohol testing based on autopsy findings or any relevant/suggestive history that may 
be available at the time [131].  
There are currently four National Health Forensic Chemistry Laboratories (FCL) in SA, which 
perform analyses on biological specimens (e.g. blood) in driving under the influence (DUI) and 
post-mortem cases. In RTAs, usually only tests for blood alcohol concentration are routinely 
performed in DUI cases. 
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In post mortem cases (includes drivers, passengers, pedestrians, motorcyclists and cyclists) the 
pathologist will use their discretion to collect biological specimens for volatiles and toxicological 
analysis based on case history and information provided. However, it is historically common 
practice amongst the pathologists to collect blood for alcohol analysis only. This is because there 
is too large of a forensic back log to be able to test these cases for other drugs as well. In post-
mortem RTF cases, as the COD is known (e.g. trauma), which is the primary mandate of the 
pathologists, many will choose not to submit specimens for additional drug testing.  
Cape Town houses one of the four FCLs, that also performs tests for Northern and Eastern Cape. 
City of Cape Town forming the metropolitan municipality has an estimated population of 
approximately 3.7 million. and is divided into East and West. In WC, there are seventeen FPS 
facilities across the province with different intake numbers based on their location.  [132]. The two 
largest mortuaries are academic and admit an average case load of 4000 suspected unnatural deaths 
per annum. One of these is Salt River Mortuary (SRM), which is associated with University of 
Cape Town (UCT) and covers the West Metropole of Cape Town [133]. 
 
3.5 Research Rationale 
There are an increasing number of studies investigating presence of substances (alcohol and other 
drugs) in RTFs. Alcohol is the most investigated substance and its effects on impairment are well 
understood. The involvement of other drugs of use and abuse must not be disregarded as their role 
in these fatalities is still not yet fully understood. 
In SA, fatal RTAs continue to be a common occurrence, contributing to the burden of violence 
and injury/trauma nationwide. Little is known on the role of substances in road traffic deaths 
locally due to limited research with some information available from organisational reports (e.g. 
WHO, South African Police Services, Road Traffic Management Centre). This information 
though, is at times, outdated and inaccurate due to underreporting, resulting in a knowledge gap.  
The lack of recent data pertaining to licit of illicit drug use is a challenge in SA, particularly in the 
forensic context where national medicolegal standards on the toxicological investigation of road 
traffic deaths are lacking.  
Internationally however, updated recommendations for toxicological investigation of motor 
vehicle fatalities were recently published [109], speaking to three tiers of  drugs and drug classes 
which should be screened for in fatal RTAs. The intention of these recommendations is the 
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standardisation of toxicological practices and improvement of the quality of data obtained from 
such cases.    
Given that international studies have reported on the presence and role of drugs in fatal RTAs, that 
there are international recommendations on the toxicological testing of such cases, and finally that 
there are high rates of RTAs and drug abuse in SA; it is apparent that there is a need to assess the 
current SA forensic toxicology practices and to interrogate drug use and patterns in fatal RTAs. 
This study was a pilot project undertaking to begin to investigate drugs in RTA cases in the West 
Metropole in Cape Town, so as to contribute to understanding this burden and identify avenues for 
further assessment in research and service in future.   
 
3.6. Aim and Objectives 
This study aimed to conduct a pilot toxicological investigation in a cohort of road traffic fatality 
deaths from SRM in Cape Town. The objectives were to: 
i. Investigate the presence of substances (other than alcohol) in a cohort of road deaths 
through toxicological screening in post-mortem biological specimens for drugs of use and 
abuse using liquid chromatography quadrupole time-of-flight mass spectrometry 
(LC/QTOF-MS). 
ii. Assess any drug trends/patterns, demographics and case characteristics identified through 
basic descriptive analysis of the RTA cohort. 
iii. Assess the applicability and utility of this type of toxicological data in road traffic research, 
and the relevance of routine toxicological investigations in these cases.   
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Chapter 4: Materials and Methods 
 
This chapter introduces the population under investigation in this preliminary prospective study 
and delves into the setting of the study, the analytical and statistical methods used, along with the 
ethical considerations involved within research of post-mortem cases. 
 
4.1 Study Population 
The population of interest for this study included all road users (drivers and passengers of any 
motor vehicle, pedestrians, motorcyclists and cyclists) involved in fatal traffic collisions, who were 
admitted to SRM between 6 June to 28 September 2018. 
A brief review of the SRM’s internal autopsy database (HREC:270/2018) (Appendix F) of cases 
admitted between 01 January 2016 and 31 December 2017, revealed that on average, there were 
344 (13% of total admissions to SRM) RTA cases annually of which only 5 (1.5%) on average 
had toxicology analysis requested. Following this review, an average of 113 RTA cases were 
identified in the four-month period (June-September) over the 2 years reviewed.  
Given that such a prospective study has not been conducted locally before and that statistics on 
post mortem case counts are not available, power calculations weren’t performed. The sample size 
estimated for this pilot study was thus 113 cases. 
 
4.2 Inclusion and Exclusion Criteria  
All cases of unnatural death other than RTAs, namely suicides, homicides, accidental and 
undetermined deaths not involving road users and/or vehicles, as well as cases in which no 
specimens (blood, urine/bile and vitreous humor) could be collected due to severe trauma were 
excluded (Figure 5.1). Cases in which only one of aforementioned specimens (excluding hair) 
could be collected were included. RTA cases in which hospitalisation and subsequent death 
occurred in a greater than 24-hour time frame were excluded. Decomposed and burned bodies in 
which samples could not be collected were omitted from the study. Children, aged younger than 
10 years old were excluded since they were unlikely to represent the general population’s drug use 
patterns. Of the 110 cases admitted, only 84 cases were eligible for the study based on the inclusion 
criteria. 
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4.3 Informed Consent in the Forensic Setting 
Written informed consent was obtained from the next-of-kin of each decedent included in the 
study. For each eligible case, a meeting between a next-of-kin of the deceased and the researcher 
was arranged with the assistance of the mortuary staff. This meeting served to provide the next of 
kin with information regarding the study, its purpose and benefits (Appendix G) and to formally 
request informed consent to collect specimens from the deceased to be used in the study. An 
informed consent form (Appendix H) was signed by the next of kin had consent been granted. 
 
4.4 Sample Collection and Storage 
For the cases in which informed consent was obtained; femoral blood, VH, urine (or bile if urine 
was unavailable) and hair were collected during autopsy. Blood samples were collected in 4 ml 
grey top tubes (Greiner Bio-One, Kremsmünster, Austria) with sodium fluoride and potassium 
oxalate. VH was collected in 4 ml plain tubes (Disera, Izmir, Turkey) without additives and 
urine/bile in 15 ml sterile centrifuge tubes (Nest Biotechnology, Jiangsu, China). These samples 
were stored in the Biomedical Forensic Science Laboratory at UCT at 4oC until sample analysis. 
Hair was collected by cutting as close to the scalp as possible to get the root ends, placed in paper 
and secured using a druggist fold, which was placed in an envelope and stored at room temperature 
[93]. 
 
4.5 Qualitative Toxicological Analysis 
4.5.1 Sample preparation  
Samples were prepared using a modified acetonitrile protein precipitation method [134]. For 
blood, VH and bile, 100 µl of the sample was aliquoted into 600 µl of acetonitrile (Merck, 
Darmstadt, Germany). With urine samples, 200 µl was aliquoted into 100 µl of acetonitrile. These 
were vortexed for ~ 5 seconds and centrifuged at 13 000 rpm for 5 minutes. The 1.5 ml screw neck 
glass vials (Macherey-Nagel GmbH & Co. KG, Düren, Germany) for blood, VH and bile had 0.3 
ml/ 6 x 31 mm wide opening, flat bottom glass inserts (Macherey-Nagel GmbH & Co. KG, Düren, 
Germany) with 200 µl of the respective sample supernatant transferred into them. The vials for 
urine also had 200 µl of the supernatant with 800 µl of ultra-pure water added to them. All the 
vials were centrifuged for ~ 5 seconds before being analysed. While using an internal standard for 
quantitative and qualitative studies is recommended, for the purpose of screening, it was deemed 
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sufficient to include in the controls. Hair was not analysed in this study due to time constraints but 
was stored at room temperature in the Biomedical Forensic Laboratory at UCT for future analyses. 
4.5.2 Screening for drugs of abuse  
The analyses were conducted at the UCT Division of Pharmacology, Groote Schuur. LC/QTOF-
MS analyses were performed on the ExionLC AC system (Sciex, Massachusetts, USA) coupled to 
a Sciex X500R QTOF-MS system (Sciex, Massachusetts, USA). Chromatographic separation was 
achieved by a phenyl hexyl Kinetex C18 column (50 mm x 4.6 mm, ID 2.6 µm) (Phenomenex, 
California, USA) at 40oC with 10 mM ammonium formate (Sigma-Aldrich, Deisenhofen, 
Germany) used as the aqueous phase (Mobile Phase A - MPA) and 0.05% formic acid in methanol 
(Merck, Darmstadt, Germany) as the organic phase (Mobile Phase B – MPB). The system was run 
in a linear gradient from 2% to 98% organic phase (MPB) over 12 min. The total run time was 
12.5 min, run at a constant flow rate 0.5 ml/min. The total volume of sample injected was 10 µl. 
The mass spectrometer ionization was performed in positive electron spray ionisation (ESI) mode. 
The ion spray voltage was 5000 V and source temperature was 500oC. 
 4.5.3 MS Data Processing 
The samples were analysed using a vSWATHTM method, which is a semi-targeted screening for 
725 drugs in a single run, which included drugs of abuse, over the counter (OTC) drugs, 
prescription drugs and endogenous compounds. The limit of detection for the method was 20 
ng/ml. Data acquisition and processing was employed using SCIEX OS software version 1.4. 
Positive detection relied on an expected retention time within ±0.5 minutes, a mass error 
confidence of ±2 ppm and a library hit score of 80% minimum. Each peak was also visually 
verified by the operator by analysing the accurate mass details related to the mass spectrum. 
 4.5.4 Quality Controls 
There were three quality controls used: Restek system suitability test mixture (Restek Corp, 
Bellefonte, PA, USA) containing amiodarone (10 µg/ml), amphetamine (10 µg/ml), caffeine (10 
µg/ml), codeine (10 µg/ml), diazepam (10 µg/ml), doxepin (10 µg/ml), haloperidol (1 µg/ml) and 
morphine (10 µg/ml). The second control was an in-house control containing drugs of abuse, 
prescription and over-the-counter compounds and the third, ultra-pure water as the negative 
control. These quality controls were analysed with every batch of the specimens and the acceptance 
criteria were the same as that for the positive detection of drugs in the specimens (section 4.5.3). 
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4.6 Data Management 
Case related information was collected regarding the date, time, area of death, scene information 
and the suspected manner and determined COD. The demographics of the decedent including age, 
sex and road user group were also recorded from South African Police Service (SAPS) and FPS 
documentation, and autopsy reports for each case. The signed consent forms were attached to the 
corresponding toxicological request forms containing the above-mentioned information for each 
case. The compiled forms were filed and kept in an access-controlled office in the Division of 
Forensic Medicine and Toxicology (UCT). To protect the sensitivity of the information collected, 
no identifying features of the deceased were stored, and all cases were assigned unique RTA study 
numbers to maintain confidentiality and anonymity. All digital case information and databases 
pertaining to the research referred to cases using the assigned RTA study numbers and were stored 
in a USB which could only be retrieved and used from the Division of Forensic Medicine and 
Toxicology. 
 
4.7 Statistical analysis 
Statistical analysis of the data was performed on STATA 13 [135]. Counts and proportions were 
tabulated for the demographic characteristics, COD and toxicological findings. For prevalence 
proportions of the detected drug groups, 95% confidence intervals were calculated. For 
comparisons between proportions, Fisher exact test was carried out where a p-value < 0.05 was 
regarded as statistically significant. In this study, comparisons were done between the 
demographic variables of the study cohort for which consent was obtained and the overall RTA 
cohort within the 4-month specimen collection period.  
 
4.8 Ethical approval 
Ethical approval for this study was granted by the University of Cape Town’s Human and Ethical 
Research Committee (HREC Ref: 270/2018). All the information used in this study was kept 
anonymous and confidential throughout the duration of study. The study was conducted in line 
with the updated Helsinki Declaration (2013). Data was obtained for the comparison of included 
and excluded cases in the study period, from the internal autopsy database, for which ethical 
approval has been obtained (HREC Ref:270/2018). 
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Chapter 5: Results 
 
5.1 Cohort Selection 
A total of 110 RTA cases were admitted into SRM during the study period. Of these, only 84 cases 
were eligible for inclusion. In 54 eligible cases, informed consent was not obtained, therefore, the 
final study cohort included 30 cases (Appendix I) that underwent qualitative toxicological analysis 
(Figure 5.1).   
 
 
 
 
 
5.2 Case Characteristics 
Of the 30 cases, the median age was 39 years old (mean: 40 years, range: 61years). The proportion 
of males (90%) was higher than that of females (10%) and pedestrians (33.3%) dominated the 
cohort (Table 5.1.). The most common COD was multiple blunt force injuries to the body (43.3%). 
The demographics of all the RTA cases admitted into SRM in the 4-month sample collection 
period are also shown in Table 5.1. The 30-case cohort and the overall RTA cases are compared 
Figure 5.1: Flow diagram of fatal RTA case selection detailing the cases admitted in the study 
period and the reasons for exclusion and cases in which consent was not obtained. 
*Unobtainable consent: Researcher was unable to meet with the family due to not being notified by    
the forensic pathology officers. 
**Denied consent: the family refused to partake in the study. 
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in terms of their proportions and there were no significant differences observed between the two 
except for the pedestrian proportions in which there was a significant difference. 
Table 5.1: Demographic characteristics of the 30 cases and overall 110 RTA cases admitted in the 4-
month period. 
*statistically significant 
 
Cohort of 30 cases  Overall RTA cases  
30 cohort vs 
overall RTA 
cases  
n 
% of total 
no. of cases 
n 
% of total 
no. of cases 
p-value 
Age      
Median age (years) 39.0 - 35.0 - - 
Sex      
Male 27 90.0 97 88.2 0.7795 
Female 3 10.0 13 11.8 0.7795 
Road user group     
Driver 6 20.0 19 17.3 0.7263 
Passenger 7 23.3 15 13.6 0.1971 
Pedestrian 10 33.3 60 54.5 0.0394* 
Motorcyclist 6 20.0 12 10.9 0.1868 
Cyclist 1 3.3 2 1.8 0.6101 
Unknown - - 2 1.8 - 
Cause of death     
Blunt force trauma - head 7 23.3 31 28.2 0.5961 
Blunt force trauma - neck 1 3.3 4 3.6 0.9362 
Blunt force trauma - chest 2 6.7 7 6.4 0.9522 
Blunt force trauma - head and chest 3 10.0 9 8.2 0.7490 
Blunt force trauma - head and pelvis 1 3.3 2 1.8 0.6101 
Blunt force trauma - chest and abdomen 2 6.7 2 1.8 0.1585 
Multiple blunt force injuries 13 43.3 49 44.5 0.9045 
Traumatic asphyxia 1 3.3 1 0.9 0.3222 
Blunt force trauma - head and neck - - 3 2.7 - 
Blunt force trauma -chest and neck - - 1 0.9 - 
Under investigation - - 1 0.9 - 
Crash Type     
Single vehicle collision 15 50.0 - - - 
Multiple vehicle collision 6 20.0 - - - 
Suburb      
Athlone 1 3.3 - - - 
Atlantis 3 10.0 - - - 
Kirstenhof 1 3.3 - - - 
Lansdowne 1 3.3 - - - 
Lentegeur 1 3.3 - - - 
Malmesbury 1 3.3 - - - 
Maitland 2 6.7 - - - 
Mannenburg 1 3.3 - - - 
Melkbosstrand 1 3.3 - - - 
Mitchells Plain 2 6.7 - - - 
Muizenburg 1 3.3 - - - 
Nyanga 7 23.3 - - - 
Phillipi 6 20.0 - - - 
Rondebosch 1 3.3 - - - 
Woodstock 1 3.3 - - - 
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In the 30 cases, the highest proportion of males killed were in the 31-40 years age group and 
females in the 41-50 years. Drivers were most represented in the 21-30- and 41-50-years age 
groups, passengers in the 41-60 years, pedestrians in the 31-40 years age group and the proportion 
of motorcyclist was highest in 21-40 years age range (Table 5.2).  
 
Table 5.2: Break down of victims by age, sex and road user group. 
  n (% proportion by age bracket) 
Age range 
(years) 
No. of 
cases 
Male Female Driver Passenger Pedestrian Motorcyclist Cyclist 
≤20 1 1 (100) - 1 (100) - - - - 
21-30 7 7 (100) - 2 (28.6) 1 (14.3) 2 (28.6) 2 (28.6) - 
31-40 9 9 (100) - 1 (11.1) 1 (11.1) 4 (44.4) 2 (22.2) 1 (11.1) 
41-50 7 5 (71.4) 2 (28.6) 2 (28.6) 2 (28.6) 2 (28.6) 1 (14.3) - 
51-60 4 100 - 1 (25.0) 2 (50.0) - 1 (25.0) - 
61-70 1 - 1 (100) - 1 (100) - - - 
70+ 1 1 (100) - - - 1 (100) - - 
 
 
5.3 Post mortem drug prevalence 
The various specimens collected for all 30 cases underwent a semi-targeted screen and a total of 
29 substances were detected and categorised into drug groups as shown in Table 5.3.  
 
Table 5.3: Detected substances categorised into drug groups. 
Drug group Specific substance detected 
Analgesics Acetaminophen 
Antidepressants Amitriptyline 
Antihistamines Chlorpheniramine, Diphenhydramine, Doxylamine, Orphenadrine 
Atypical 
antipsychotics 
9-Hydroxyrisperidone 
CNS stimulant Amphetamine, Caffeine, Methamphetamine 
Opioidss/opiates Codeine, Codeine glucuronide, Hydromorphone, Morphine 
Parasympathetic 
stimulant 
Cotinine, Nicotine 
Other 
prescription/OTC 
drugs 
Chinine, Gliclazide, Ketamine and Norketamine, Lidocaine, Nicotinamide, 
Theophylline, Tranexamic acid, Quinidine, Quinine, Warfarin 
Sedative-
hypnotics 
Methaqulone, Zopiclone 
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The prevalence of each drug group as is represented in Figure 5.2 with the three most prevalent 
drug groups being CNS stimulants (20 cases), other prescription/OTC drugs (20 cases) and 
parasympathetic stimulants (9 cases). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.4 Specific drug detections in each road user group 
Drugs (other than alcohol) were detected in in 27 (90%) of the cases, of which 26 (96%) had 
multiple substances present (Appendix I). The specific drugs detected per road user group are 
shown in Table 5.4. The most prevalent legal substances were caffeine (n=20) and nicotinamide 
(n=16). These substances were detected in all the road user groups except the single cyclist case. 
The most common illegal substances detected were methaqualone (n=3) and methamphetamine 
(n=2) which were detected in pedestrians only. The most frequent substance detections for drivers 
were antihistamines and other prescription/OTC drugs whereas pedestrians and motorcyclists were 
frequently positive for the other prescription/OTC drugs. 
 
 
 
Figure 5.2: Prevalence (as a percentage) of drug groups detected in the 30 cases. 
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Table 5.4: Specific drug substances detected in each road user group. 
     n (% proportion of total no. of cases)  
Drug group 
No. of 
cases 
Driver Passenger Pedestrian Motorcyclist Cyclist 95% CI 
Negative 3 - 2 (6.7)  - 1 (3.3)  - 0.026 - 0.276 
               
Analgesics 6           0.084 - 0.391 
Acetaminophen   2 (6.7) 3 (10.0) - 1 (3.3) -  
               
Antidepressants 1           0.002 - 0.191 
Amitriptyline   - - 1 (3.3) - -  
               
Antihistamines 6           0.084 - 0.391 
Chlorpheniramine   2 (6.7) 1 (3.3) - 1 (3.3) -  
Diphenhydramine   2 (6.7) - 1 (3.3) - -  
Doxylamine   1 (3.3) - - - -  
Orphenadrine   1 (3.3) - - - -  
               
Atypical antipsychotics 1           0.0017 - 0.1905 
9-Hydroxyrisperidone   - - 1 (3.3)  - -  
               
CNS stimulant 20           0.471 - 0.820 
Amphetamine   - - 1 (3.3) - -  
Caffeine   4 (13.3) 5 (16.7) 7 (23.3) 4 (13.3) -  
Methamphetamine       2 (6.7)      
               
Opioids/opiates 4           0.0434 - 0.316 
Codeine   1 (3.3) - - - -  
Codeine glucuronide   1 (3.3) 1 (3.3) - - -  
Hydromorphone   - - - 1 (3.3) 1 (3.3)  
Morphine   - - - 1 (3.3) 1 (3.3)  
               
Parasympathetic stimulant 10           0.179 - 0.529 
Cotinine     1 (3.3) 1 (3.3) 5 (16.7) 2 (6.7) -  
Nicotine   2 (6.7) - 3 (10.0) 1 (3.3) -  
               
Other prescription/OTC 
drugs 
20           
0.471 - 0.820 
Chinine   - - 1 (3.3)  - -  
Gliclazide   - - 1 (3.3) 1 (3.3) -  
Ketamine   1 (3.3) - - 1 (3.3) -  
Lidocaine   1 (3.3) - - 1 (3.3) -  
Nicotinamide   4 (13.3) 2 (6.7) 6 (20.0) 4 (13.3) -  
Norketamine   - - - 1 (3.3) -  
Theophylline    - - - 1 (3.3) -  
Tranexamic acid   - - - 1 (3.3) -  
Quinidine   - - 1 (3.3) - -  
Quinine   - - 2 (6.7) - -  
Warfarin   - - - 1 (3.3) -  
               
Sedative-hypnotics 5           0.063 - 0.355 
Methaqulone   1 (3.3) - 3 (10.0) - -  
Zopiclone   - - - 1 (3.3) -  
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5.5 Road user groups, medico-legal findings and collision types 
The most common COD among all road user groups was multiple blunt force injuries to the body 
and the second most common COD was blunt force trauma to the head. Drivers and motorcyclists’ 
COD were mainly blunt force trauma to head and the body, passengers had trauma injuries to the 
chest and to the body and pedestrians mostly had head and chest and body blunt trauma injuries 
(Fig 5.3A). Single vehicle collisions (SVC) accounted for 15 (50%) of all the cases and multiple 
vehicle collisions (MVC) 6 (20%) cases. Pedestrians and motorcyclists were mostly involved in 
SVC whereas drivers were slightly more involved in MVCs (Fig 5.3B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 5.3: Distribution of (A) cause of death by blunt force trauma to various 
body parts and (B) SVC and MVC in the road user groups. 
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Chapter 6: Discussion and Conclusions 
 
RTFs are a common occurrence across the world and contribute widely to the burden of injury and 
mortality. There is an increased risk of being involved in an RTA as a road user, when impaired 
by drugs and/or alcohol. This may result in death, in which the presence of drugs and alcohol can 
be detected and interpreted by forensic toxicologists.  
In the South African forensic setting, there is no standardised protocol for toxicological analysis 
in RTA fatalities, despite publication of international recommendations of toxicological analysis 
in road user deaths. While blood for alcohol is largely routinely collected in RTA deaths in the 
WC, in SA, the potential involvement of substances (drugs other than alcohol) in the contribution 
or COD in road traffic victims cannot be overlooked.  
The systematic literature review (Chapter 2) on the global reported prevalence of drugs of abuse 
in RTFs revealed that most research on this topic was conducted in developed countries, despite 
the largest burden of RTFs occurs in under-developed and developing nations. Additionally, the 
review highlighted the common occurrence of intoxicating drugs other than alcohol in victims of 
RTAs and the importance of forensic toxicological testing in these cases. Furthermore, the review 
highlighted the need for similar studies in such developing countries in which the findings could 
be compared both nationally and internationally. This pilot study was conducted to initiate the 
bridging of the gap in this area in SA.  
Drug abuse is a problem in Cape Town, with research suggestion a wide prevalence of 
methamphetamine, cannabis and methaqualone (mandrax) use in the WC (in addition to alcohol). 
The presence of these, and other licit psychoactive drugs in the RTA population, is unknown within 
the South African forensic context. 
To the author’s knowledge, this pilot study was the first, to report on the toxicological findings in 
fatal RTAs in Cape Town, SA, and is in congruence with other research in the presence of 
substances (legal or illicit) in fatal RTAs. 
 
 
 
 
 
   
Toxicological Findings in Road Traffic Accidents   
  43 
 
6.1 A Cohort of Road Traffic Deaths from Salt River Mortuary  
The study cohort comprised of 30 cases of which most were male, pedestrians and had an average 
age of 40 years old. The overall RTA deaths in the study period (n=110) were also predominantly 
male (88%). This correlates with other studies in which the proportion of males was higher than 
that of females [60, 63, 70]. Research investigating an individual’s sex and driving behaviour have 
found that males tend to take more risks while driving than females [136, 137]. In addition, males 
are more likely to violate traffic laws (drinking and driving and driving above speed limits) than 
their female counterparts, thus suggesting their involvement in more traffic accidents [138]. 
Another aspect is that generally, the rates of alcohol and drug use and abuse are higher in men than 
in women, however, use, abuse or dependence patterns differ by drug and age group [139, 140].  
In terms of drugs, alcohol consumption and abuse is significantly higher in men than in women of 
age group 25-34 years [141], although there has been a decrease in this gender gap over time [142]. 
Instead, women engage more in the non-medical use of prescription type drugs i.e. opioids and 
tranquilisers [143] particularly women of the older age group of 65 years and older age group 
[141]. Men are more likely to use cannabis in individual aged 18-24 years, with no variation in 
those aged 25 years [141] and older. whereas, the use of stimulants is similar between both sexes 
[144] across all age groups [141]. 
RTAs mostly affect individuals who are young and those in the working class in their prime 
working years. This age group is generally defined as those aged between 15-64 years [145]. Most 
of the cases in this study were specifically within the age range of 31-40 years with an average age 
of 40 years and this similar to the age range found in a study of drugs and fatal traffic accidents in 
the Czech Republic where the average age was in that study was 42.2 years [63]. A study by Al-
Balbissi [146] found that highest accident rates were in 36-50 years age group and suggested that 
this might be attributed to the overconfidence of this age group in their driving abilities. 
While the study size is small, pedestrians were identified as a vulnerable group, both in the cohort 
and the overall admissions in the study period. This is consistent with reports that this road user 
group has been noted to be a vulnerable group, particularly in developing countries [5, 13]. In 
studies reporting toxicological findings in all road user groups, some illustrate that pedestrians 
were the group mostly affected and the most prevalent drugs found in this vulnerable group were 
alcohol, stimulants (e.g. amphetamine, methamphetamine), cannabis and benzodiazepines [53, 57, 
63, 64]. 
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The demographic variables of this cohort of 30 cases were compared to those of the overall RTA 
cases admitted into SRM within the 4-month period. This was done to determine how 
representative the study cohort was to the actual fatal RTA population within the 4-month sample 
collection period at the SRM mortuary. Apart from the proportion of pedestrians - which in the 
overall RTA cases was significantly larger (p < 0.05) - there were no statistically significant 
differences between the other groups, suggesting that the study cohort was similar 
demographically to the overall RTA population.  
 
Although the study cohort was similar to the larger 4-month overall RTA population, this does not 
account for the over population of RTF’s in West-Metropole of Cape Town. The researcher 
recognises the limitation that this cohort may not be truly representative of the annual RTF 
admissions to Salt River and may not represent the larger Cape Town population. This requires 
wider investigations.  
 
6.2 Post-mortem Drug Findings in the RTF Cohort 
In the cohort of 30 cases investigated, 27 were positive for licit and/or illicit drugs, excluding 
alcohol, which was not the focus of this investigation. The most prevalent legal substances detected 
were caffeine and nicotinamide. Caffeine is a CNS stimulant which suppresses adenosine- a 
mediator of sleep [147] thus activating alertness. CNS stimulants have been reported as one of the 
most prevalent drug groups in fatal RTAs,  but the specific drugs reported were amphetamines, 
methamphetamines, cocaine and methylenedioxymethamphetamine (ecstasy) [56, 63, 64, 82, 84]. 
Although caffeine has not been reported as prevalent drug in other similar studies, a study 
examined the effects of caffeine vs placebo on driving performance in regular consumers of 
caffeine who were deprived of caffeine prior to being tested. Interestingly, the findings suggest 
that increased alertness and improved driving performance are exaggerated effects of caffeine 
withdrawal as opposed to the effect of caffeine actually being beneficial [148]. Contrary to this 
though, another study also looking at effects of caffeine on driving found that one cup of 
caffeinated coffee had a positive effect on driving performance [149].  
Nicotine activates the same reward pathways as other drugs of abuse (e.g. amphetamines, cocaine) 
but to a lesser extent [150] and produces small improvements in cognitive performance and 
attention [151]. Cotinine, which accumulates in the body due to tobacco exposure [152] can be 
looked at, along with nicotine to get an indication of tobacco smokers – whom, if deprived of 
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tobacco, can experience impairment in their cognition [153]. This impairment, due to deprivation, 
could potentially affect driving abilities. 
Amphetamines are stimulants which have long been used medically to treat attention deficit 
hyperactivity disorder (ADHD) and narcolepsy but they do have a high potential of being abused 
[154]. This potential of abuse leads to drug related RTFs. A systematic review on the RTI or death 
risk due to amphetamine-type stimulants reported a moderate relationship between the use of 
amphetamine type stimulants and risk of fatally injury in an RTA, based on the 9 studies included 
in that review [155]. Additionally, even though this drug is a stimulant, other studies have reported 
on the driving impairment effects of at high doses [156, 157]. 
Nicotinamide, also known niacinamide is a form of vitamin B3 which is an OTC drug available as 
cosmetic, hair and skin preparation and can also be found in certain foods such as meat, dairy 
products, green vegetables and even coffee [158]. Associated use of OTC drugs and alcohol (a 
CNS depressant) can intensify the impairment effects of prescription/OTC drugs even though the 
drug may not ordinarily cause impairment on its own and patient are advised to not drive unless 
aware of individual response to medication [66]. OTC drugs have been detected in fatal RTA 
studies [60, 71] but none have detected nicotinamide. 
Antihistamines, another group of OTC/prescription drugs, were frequently detected particularly 
among the drivers in this study. They are inverse agonists of histamines. Histamines are chemical 
messengers in the body which regulate the proliferation and differentiation of cells, regulate 
sleep/wake cycles, and alertness and attentiveness. First generation antihistamines such as 
chlorpheniramine, diphenhydramine and doxylamine may cause sedation, drowsiness, tiredness 
and lack of attention and concentration. Second generation antihistamines, however, have reduced 
effects on the CNS [159].  
Vester and Volkerts reported that both first and second-generation antihistamines may 
significantly reduce driving performance after single and repeated consumption (without alcohol) 
[160]. Another study concurred with findings that both first and second-generation antihistamines 
may cause driving impairment, however, their conclusion was there was no significant relative 
risk associated with antihistamine use and traffic accidents [161]. As with other OTC/prescription 
drugs, the sedative effects of antihistamines is increased when used in combination with alcohol 
[162]. 
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The two common illicit drugs detected were methaqualone and methamphetamine (and 
amphetamine its primary metabolite). Methaqualone (usually admixed with drugs such as 
diphenhydramine and orphenadrine) known as mandrax in SA is a sedative hypnotic drug which 
was used for insomnia, hypertension and anxiety due to its CNS depressant effects [163] This drug 
also has euphoric and aphrodisiac properties which contributed to its high recreational use and 
subsequent abuse [164]. In SA this drug is sold in tablet form and normally crushed, mixed with 
cannabis and smoked in a cannabis pipe, this is known as white pipe or ‘wit pyp’ [163, 165] The 
combination of the two drugs produces a greater “rush” effect [166]. Methamphetamine is another 
commonly abused synthetic drug in SA colloquially known as ‘tik’. Tik is a highly addictive 
stimulant with euphoric and increased energy effects [167].  
These drugs have been reported in other RTF cases. Two studies reported the presence of 
methamphetamines in fatally injured drivers, more so in truck drivers who drove long distances 
[82, 168]. In another study by Logan, the driving behaviour which led to the accident of 
methamphetamine-positive drivers was said to be more consistent with methamphetamine 
withdrawal whose effects are as problematic as the intoxication [169]. 
Methaqualone has been noted to cause significant driving impairment [170] but in another study, 
the presence of methaqualone in four drivers was determined to have not contributed to the 
accidents and in one case in which alcohol was also detected, the level of intoxication with alcohol 
would have likely led to the accident with or without the presence of methaqualone [33].  
Opioids/opiates (i.e morphine, hydrocodone and codeine), zopiclone and amitriptyline all have 
sedative effects in common, although they classify under different drug groups. Opioid use was 
found to significantly increase crash involvement and culpability [171] and codeine having a dose 
dependent effect which may lead to driving impairment [172]. The acute doses of amitriptyline 
significantly reduced driver vigilance and impaired driving performance [173]. Similarly, 
zopiclone also reduced driver performance, however, less so for chronic users compared to new 
users [174, 175].  
It is important to note that the presence of drugs detected does not necessarily correlate to the level 
of intoxication of the user at the time of death, nor was it an indicator (particularly of drugs known 
to have impairing effects), that the drug was the causal factor of the accident. Quantification of the 
drugs and further research into effects of drugs as well as an evaluation of the case histories and 
circumstantial evidence of the accidents would be required to be able to make conclusions 
pertaining to the possible involvement of the drugs detected in the fatal RTAs of this study. 
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6.2.1 Case Study 
While the exact role of drugs cannot be ascertained, this study provides a proof of concept of the 
importance of drug testing in RTFs. This can be illustrated by the following specific cases derived 
from the cohort.  
Case 8: 
The deceased was a 19-year-old male driver. The deceased was the only victim involved in an 
MVC on a wet, tar road with speed limit of 120 km/h. Toxicology analysis revealed 
chlorpheniramine, diphenhydramine and codeine detected in the blood. Blood alcohol analysis 
(performed by the external FCL laboratory) was negative.  
Substances detected in blood were antihistamines and the opiate, codeine. These drugs can have 
possible impairing effects such as causing sedation. The drug testing performed in this study 
revealed the presence of these impairing drugs in this case which otherwise would not have been 
detected as samples for these cases (RTA cases) had only been sent for BAC analysis, as is 
routinely done. The nature of the role of these drugs in contributing the death would require further 
investigation, including the quantitation of those substances together with further evaluation by 
the forensic toxicologist and pathologist.  
 
6.3 Road user groups, medicolegal findings and collision types 
The two most observed CODs overall were head trauma and multiple trauma injuries to the body.  
Similar to the findings in this study, other studies found that one of the most common causes of 
death was injuries to the head [176-178]. Passengers in this study mostly succumbed to blunt force 
trauma to the chest. A proposed reason for this is that the lack of a steering wheel may result in a 
much greater forward momentum and the impact and force is directed right on the chest and 
abdomen of the passenger [179].  
The SVCs were more prevalent than the MVCs. These SVCs happened on tar roads, in good 
condition with speed limits ranging from 60-120 km/h. In terms of motorised vehicles, these 
collisions were mostly motorcyclists (10%) who had caffeine, nicotine and cotinine (stimulants) 
and zopiclone (sedative hypnotic) detected. One motorcyclist had no drugs detected. The other 
road user group involved in SVCs were pedestrians (50%) with same drug groups detected. This 
might suggest a positive relationship between impairment by road users and drugs [56]. 
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6.4 Limitations 
As with all research, there were some limitations in this study. Although this was a pilot study, the 
sample size of 30 cases constrained the investigation into demographic distribution and 
toxicological and medicolegal findings of the cases. These cases may not represent the overall 
RTF cohort admitted to SRM annually, nor the WC mortuary population. In addition, while insight 
into the drugs detected is provided, this study did not provide a true representation of the drugs 
that may or may not be within the WC population of road users. 
Obtaining consent from the next-of-kin, which is essential in forensic research and investigating 
such vulnerable populations, was a challenge in this project. This process required a collaborative 
effort with the mortuary Forensic Pathology Officers (FPOs), who would notify the researcher 
when a family for an eligible case was at the mortuary. However, due to the FPOs large workload, 
a substantial number of families were missed, and consent was unable to be obtained. Along with 
this, there was a time constraint in that the sample collection period was limited to 4 months based 
on the timeline of the research project as a whole. Getting consent is important to conduct research 
where the outcomes are currently unknown and improving this process of notification would be of 
value to future projects. One suggestion to overcome this is for the researcher to screen the files of 
the cases admitted to the mortuary daily and mark the eligible cases which would serve as a 
reminder for the FOs to contact the researcher should the next-of-kin arrive at the mortuary and 
secondary to that, for the researcher to be “based” at the mortuary premises/facility throughout the 
specimen collection period. In addition, a longer specimen collection period could increase the 
number of cases obtained for such a study. 
While the LC-QTOF/MS provides screening capabilities in high resolution, a quantitative 
confirmation would be required in these cases, especially in routine forensic practice. This would 
provide improved probative weight to the findings and allow for greater interpretation by the 
forensic toxicologist. The research is also cognisant of the importance of validation of analytical 
methods. This study did not permit for validation procedures to be carried out, and the method that 
is currently available at the Division of Pharmacology was used as developed. This limitation is 
one that would need to be accounted for in routine service and especially in quantitative methods, 
where validation for the specific drugs in the post-mortem specimens would be required.  
The limit of detection for concentrations of THC from cannabis use was high on the LC-QTOF/MS 
and it was recommended that urine be analysed on an immunoassay. This would only illustrate 
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exposure, however, and won’t provide an indication of timing of use nor provide any indication of 
impairment. In future the method needs to be validated for THC, 11-nor-9-carboxy-delta 9-
tetrahydrocannabinol (THCCOOH) and 11-hydroxy tetrahydrocannabinol (THCOH) to determine 
the prevalence and concentrations of THC in these cases. 
Because of the small study size and the descriptive nature of this study, performing certain 
statistical tests to determine significant differences or lack thereof of prevalence of drugs between 
the different road user groups was not possible. Such statistical tests are important in adding 
strength and certainty to the findings and the conclusions thereof and could be undertaken with a 
more comprehensive sample size. 
Another limitation to the study was the lack of a control group. All the specimens tested were from 
a deceased RTA cohort. An ideal control group would be living drivers who were pulled over 
randomly for drug testing and/or for DUI. Such a control would allow for comparison of drug 
prevalence between the deceased RTA population and the general road user population. Lack of 
such a control group means it is also not possible to infer whether the prevalence of drug use is 
higher among the deceased road users or the general road user population. 
  
6.5 Future research 
The preliminary findings in this study have highlighted the need for future research in this area. 
The first of which would be to continue this research in a larger study cohort and investigate the 
drug trends in these cases. 
The BACs were not discussed in this project, as these were performed by the National Health FCL. 
Including these results when available to include the relevance of both drugs and/or alcohol in 
these cases is essential in going forward to recommend best practice. This will assist in 
understanding of the extent of the relationship between alcohol and drugs and their additive effects 
in causing impairment in the different road users within the local context. This pilot study provided 
important information concerning the requirements for developing future research and the roll-
over into best practice within the WC. 
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6.6 Conclusion 
This study was a pilot study to investigate the toxicological findings in a cohort of RTA fatalities 
in the West Metropole of Cape Town and gain insight into the drugs detected in such cases. 
Although the findings are limited, this study has brought to the forefront that drugs are present in 
the road user population and further insight into the role of these drugs together with alcohol in 
RTFs is required. Most cases were positive for a substance (other than alcohol – which was not 
investigated in this study), and prescription drugs appeared to dominate the cohort. Many drugs 
with psychoactive and/or sedative/hypnotic properties were identified within the cohort.  
Despite the fact that the study size was small, and no inferences can be made about the general 
population, the results of this study have set a basis for future research which would most certainly 
contribute to the body of literature on this topic - considering that such a study had not yet been 
done in the South African setting. 
It is important to reiterate that with nature of this study, the presence of the drugs at the time of 
death do not infer on causation of the accidents. After all, RTAs are multifactorial and to determine 
the role that drugs might have had in the accident is complex and would require more rigorous 
investigations and interpretive expertise. A key aspect to keep in mind in future research is using 
the information to develop a standardised protocol for the routine collection and analyses of 
specimens for such cases, specifically suited for the context and setting of SA. 
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Appendices 
 
Appendix A - Scopus search strategy 
 
Search # Search texts and syntaxes 
#1 TITLE-ABS-KEY (road user OR road users OR driver OR drivers OR passenger OR passengers OR 
motorcyclist OR motorcyclists OR cyclist OR cyclists OR pedestrian OR pedestrians) 
#2 TITLE-ABS-KEY (drug OR drugs OR illicit drug OR illicit drugs OR licit drug OR licit drugs) 
#3 TITLE-ABS-KEY (illegal drug OR illegal drugs OR legal drug OR legal drugs) 
#4 TITLE-ABS-KEY (substance OR substances OR non-alcoholic drugs OR non alcoholic drugs) 
#5 TITLE-ABS-KEY (street drug OR streets drugs OR recreational drug OR recreational drugs) 
#6 TITLE-ABS-KEY (psychotropic drug OR psychotropic drugs OR drug of abuse OR drugs of abuse) 
#7 TITLE-ABS-KEY (psychoactive drug OR psychoactive drugs OR psychotic drug OR psychotic drugs) 
 
#8 #2 OR #3 OR #4 OR #5 OR #6 OR #7 
#9 TITLE-ABS-KEY (road traffic accident OR road traffic accidents OR traffic accident OR traffic 
accidents) 
#10 TITLE-ABS-KEY (motor vehicle accident OR motor vehicle accidents OR motor vehicle crash OR 
motor vehicle crashes OR motor-vehicle crash OR motor-vehicle crashes) 
#11 TITLE-ABS-KEY (road-traffic crash OR road-traffic crashes OR road traffic crash OR road traffic 
crashes OR traffic crash OR road crash OR road crashes) 
#12 TITLE-ABS-KEY (traffic collision OR traffic collisions OR road traffic collision OR road traffic 
collisions) 
#13 #9 OR #10 OR #11 OR #12 
#14 TITLE-ABS-KEY (fatality OR mortality OR casualty OR death OR fatal OR dead OR die OR died) 
#15 #1 AND #8 AND #13 AND #14 
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Appendix B – Final search terms and filters for all databases 
 
 
Database 
Search terms Articles 
retrieved 
Articles 
included 
PubMed 
Sort by: Most recent 
 
 (((((fatality OR mortality OR casualty OR death OR fatal OR dead OR die OR died))) AND ((road traffic accident 
OR road traffic accidents OR traffic accident OR traffic accidents OR motor vehicle accident OR motor vehicle 
accidents OR motor vehicle crash OR motor vehicle crashes OR motor-vehicle crash OR motor-vehicle crashes 
OR road-traffic crash OR road-traffic crashes OR road traffic crash OR road traffic crashes OR traffic crash OR 
road crash OR road crashes OR traffic collision OR traffic collisions OR road traffic collision OR road traffic 
collisions))) AND ((((drug OR drugs OR illicit drug OR illicit drugs OR licit drug OR licit drugs OR illegal drug OR 
illegal drugs OR legal drug OR legal drugs OR substance OR substances OR non-alcoholic drugs OR non 
alcoholic drugs OR recreational drug OR recreational drugs OR drug of abuse OR drugs of abuse OR 
psychoactive drug OR psychoactive drugs OR psychotic drug OR psychotic drugs OR street drug OR 
psychotropic drug)) OR "Psychotropic Drugs"[MeSH]) OR "Street Drugs"[MeSH])) AND (((((((road user OR road 
users)) OR (driver OR drivers)) OR (passenger OR passengers)) OR (cyclist OR cyclists)) OR (pedestrian OR 
pedestrians)) OR (motorcyclist OR motorcyclists 
380 35 
Scopus 
( TITLE-ABS-KEY ( road  AND  user  OR  road  AND  users  OR  driver  OR  drivers  OR  passenger  OR  
passengers  OR  motorcyclist  OR  motorcyclists  OR  cyclist  OR  cyclists  OR  pedestrian  OR  pedestrians ) )  
AND  ( ( TITLE-ABS-KEY ( drug  OR  drugs  OR  illicit  AND drug  OR  illicit  AND drugs  OR  licit  AND drug  OR  
licit  AND drugs ) )  OR  ( TITLE-ABS-KEY ( illegal  AND drug  OR  illegal  AND drugs  OR  legal  AND drug  OR  
legal  AND drugs ) )  OR  ( TITLE-ABS-KEY ( substance  OR  substances  OR  non-alcoholic  AND drugs  OR  
non  AND alcoholic  AND drugs ) )  OR  ( TITLE-ABS-KEY ( street  AND drug  OR  streets  AND drugs  OR  
recreational  AND drug  OR  recreational  AND drugs ) )  OR  ( TITLE-ABS-KEY ( psychotropic  AND drug  OR  
psychotropic  AND drugs  OR  drug  AND of  AND abuse  OR  drugs  AND of  AND abuse ) )  OR  ( TITLE-ABS-
KEY ( psychoactive  AND drug  OR  psychoactive  AND drugs  OR  psychotic  AND drug  OR  psychotic  AND 
drugs ) ) )  AND  ( ( ( TITLE-ABS-KEY ( road-traffic  AND crash  OR  road-traffic  AND crashes  OR  road  AND 
traffic  AND crash  OR  road  AND traffic  AND crashes  OR  traffic  AND crash  OR  road  AND crash  OR  road  
AND crashes ) )  OR  ( TITLE-ABS-KEY ( traffic  AND collision  OR  traffic  AND collisions  OR  road  AND traffic  
AND collision  OR  road  AND traffic  AND collisions ) ) )  OR  ( ( TITLE-ABS-KEY ( road  AND traffic  AND 
accident  OR  road  AND traffic  AND accidents  OR  traffic  AND accident  OR  traffic  AND accidents ) )  OR  ( 
TITLE-ABS-KEY ( motor  AND vehicle  AND accident  OR  motor  AND vehicle  AND accidents  OR  motor  AND 
vehicle  AND crash  OR  motor  AND vehicle  AND crashes  OR  motor-vehicle  AND crash  OR  motor-vehicle  
AND crashes ) ) ) )  AND  ( TITLE-ABS-KEY ( fatality  OR  mortality  OR  casualty  OR  death  OR  fatal  OR  
dead  OR  die  OR  died ) ) 
214 1 
Web of 
Science 
Indexes=SCI-EXPANDED, SSCI, A&HCI, ESCI Timespan=All years 
 
TITLE: (road user OR road users OR driver OR drivers OR passenger OR passengers OR motorcyclist OR 
motorcyclists OR cyclist OR cyclists OR pedestrian OR pedestrians) AND TITLE: (drug OR drugs OR illicit drug 
OR illicit drugs OR licit drug OR licit drugs OR illegal drug OR illegal drugs OR legal drug OR legal drugs OR 
substance OR substances OR non-alcoholic drugs OR non alcoholic drugs OR street drug OR streets drugs OR 
recreational drug OR recreational drugs OR psychotropic drug OR psychotropic drugs OR drug of abuse OR 
drugs of abuse OR psychoactive drug OR psychoactive drugs OR psychotic drug OR psychotic drugs) AND 
TITLE: (road traffic accident OR road traffic accidents OR traffic accident OR traffic accidents OR motor vehicle 
accident OR motor vehicle accidents OR motor vehicle crash OR motor vehicle crashes OR motor-vehicle crash 
OR motor-vehicle crashes OR road-traffic crash OR road-traffic crashes OR road traffic crash OR road traffic 
crashes OR traffic crash OR road crash OR road crashes OR traffic collision OR traffic collisions OR road traffic 
collision OR road traffic collisions) AND TITLE: (fatality OR mortality OR casualty OR death OR fatal OR dead 
OR die OR died) 
 
7 1 
CINAHL 
Limiters - Full Text; Peer Reviewed Search modes - Boolean/Phrase 
 
(road user OR road users OR driver OR drivers OR passenger OR passengers OR motorcyclist OR motorcyclists 
OR cyclist OR cyclists OR pedestrian OR pedestrians) AND (drug OR drugs OR illicit drug OR illicit drugs OR 
licit drug OR licit drugs OR illegal drug OR illegal drugs OR legal drug OR legal drugs OR substance OR 
substances OR non-alcoholic drugs OR non alcoholic drugs OR street drug OR streets drugs OR recreational 
drug OR recreational drugs OR psychotropic drug OR psychotropic drugs OR drug of abuse OR drugs of abuse 
OR psychoactive drug OR psychoactive drugs OR psychotic drug OR psychotic drugs) AND (road traffic accident 
OR road traffic accidents OR traffic accident OR traffic accidents OR motor vehicle accident OR motor vehicle 
accidents OR motor vehicle crash OR motor vehicle crashes OR motor-vehicle crash OR motor-vehicle crashes 
OR road-traffic crash OR road-traffic crashes OR road traffic crash OR road traffic crashes OR traffic crash OR 
road crash OR road crashes OR traffic collision OR traffic collisions OR road traffic collision OR road traffic 
collisions) AND (fatality OR mortality OR casualty OR death OR fatal OR dead OR die OR died) 
 
5 0 
Grey 
literature 
Search : keywords No limits set 
 
(road user OR road users OR driver OR drivers OR passenger OR passengers OR motorcyclist OR motorcyclists 
OR cyclist OR cyclists OR pedestrian OR pedestrians) AND (drug OR drugs OR illicit drug OR illicit drugs OR 
licit drug OR licit drugs OR illegal drug OR illegal drugs OR legal drug OR legal drugs OR substance OR 
substances OR non-alcoholic drugs OR non alcoholic drugs OR street drug OR streets drugs OR recreational 
drug OR recreational drugs OR psychotropic drug OR psychotropic drugs OR drug of abuse OR drugs of abuse 
OR psychoactive drug OR psychoactive drugs OR psychotic drug OR psychotic drugs) AND (road traffic accident 
OR road traffic accidents OR traffic accident OR traffic accidents OR motor vehicle accident OR motor vehicle 
accidents OR motor vehicle crash OR motor vehicle crashes OR motor-vehicle crash OR motor-vehicle crashes 
OR road-traffic crash OR road-traffic crashes OR road traffic crash OR road traffic crashes OR traffic crash OR 
road crash OR road crashes OR traffic collision OR traffic collisions OR road traffic collision OR road traffic 
collisions) AND (fatality OR mortality OR casualty OR death OR fatal OR dead OR die OR died) 
33 0 
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Appendix C – Adapted JBI Extraction Form 
 
  
Study ID 
Author  
Article title  
Year published  
Country 
Study period  
Aims  
Study design  
Population of interest  
Sample size studied  
 
Methods (toxicological analyses and statistical tests) 
Tests done in methods 
Instruments used  
Statistical significance (p-value or CI)  
Measurement of outcome variables (prevalence or prevalence odds ratio/rates)  
Outcome variables 
  
Results 
Basic demographics data 
Prevalence n/N (%) 
Incidence n/N (%) 
Specific drugs 
  
Exclusions in population of interest 
Study limitations  
Ethical approval attained  
Informed consent  
Appraisal quality rating  
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Appendix D – AXIS Critical Appraisal Tool for Cross-sectional Studies 
 
Section Question Yes No Don’t know/ 
Comment 
Introduction     
1  Were the aims/objectives of the study clear?    
Methods     
2  Was the study design appropriate for the stated aim(s)?    
3  Was the sample size justified?    
4  
Was the target/reference population clearly defined? (Is it clear 
who the 
research was about?) 
 
  
5  
Was the sample frame taken from an appropriate population 
base so that it 
closely represented the target/reference population under 
investigation? 
 
  
6  
Was the selection process likely to select subjects/participants 
that were 
representative of the target/reference population under 
investigation? 
 
  
7  Were measures undertaken to address and categorise non-
responders? 
   
8  
Were the risk factor and outcome variables measured 
appropriate to the aims 
of the study? 
 
  
9 
Were the risk factor and outcome variables measured correctly 
using 
instruments/measurements that had been trialled, piloted or 
published 
previously? 
 
  
10  
Is it clear what was used to determined statistical significance 
and/or 
precision estimates? (e.g. p-values, confidence intervals) 
 
  
11  
Were the methods (including statistical methods) sufficiently 
described to 
enable them to be repeated? 
 
  
Results     
12  Were the basic data adequately described?    
13  Does the response rate raise concerns about non-response bias?    
14  If appropriate, was information about non-responders 
described? 
   
15  Were the results internally consistent?    
16  Were the results presented for all the analyses described in the 
methods? 
   
Discussion     
17  Were the authors' discussions and conclusions justified by the 
results? 
   
18  Were the limitations of the study discussed?    
Other     
19  
Were there any funding sources or conflicts of interest that may 
affect the 
authors’ interpretation of the results? 
 
  
20  Was ethical approval or consent of participants attained    
 
Quality rating (Good, fair or poor)  
Rater’s initials  
Additional comments (if poor please state why) 
 
   
Toxicological Findings in Road Traffic Accidents     70 
 
Appendix E – List of all articles included in the review 
 
Reference 
number 
First author Article title 
Year 
published 
Country 
[40] Bogstrand et al 
Associations between driving under the influence of alcohol or drugs, speeding and seatbelt use among fatally 
injured car drivers in Norway. 
2015 
Norway 
[41] Brady et al. Prevalence of alcohol and other drugs in fatally injured drivers. 2013 US 
[42] Carmen del Rio et al. Alcohol, illicit drugs and medicinal drugs in fatally injured drivers in Spain between 1991 and 2000. 2002 Spain 
[43] Christophersen et al Prevalence of alcohol and drugs among motorcycle riders killed in road crashes in Norway during 2001-2010. 2015 Norway 
[44] Drummer et al. The incidence of drugs in drivers killed in Australian road traffic crashes. 2003 Australia 
[45] Isalberti et al. Prevalence of alcohol and other psychoactive substances in injured and killed drivers 2011 
Finland, Norway, Portugal, 
Sweden 
[46] Legrand et al. Prevalence of alcohol, illicit drugs and psychoactive medicines in killed drivers in four European countries. 2014 
Finland, Norway, Portugal, 
Sweden 
[47] Poulsen et al. The incidence of alcohol and other drugs in drivers killed in New Zealand road crashes 2004-2009. 2012 New Zealand 
[48] Rudisill et al. Trends in drug use among drivers killed in U.S. traffic crashes, 1999-2010. 2014 US 
[49] Rudisill et al 
Characterization of drug and alcohol use among senior drivers fatally injured in U.S. motor vehicle collisions, 
2008-2012. 
2016 
US 
[50] Schwilke et al. Changing patterns of drug and alcohol use in fatally injured drivers in Washington State. 2006 US 
[51] Ahlm et al. Alcohol and drugs in fatally and non-fatally injured motor vehicle drivers in northern Sweden. 2009 
Sweden 
[52] Ahlner et al. 
Prevalence of alcohol and other drugs and the concentrations in blood of drivers killed in road traffic crashes in 
Sweden. 
2014 
Sweden 
[53] Al-Abdallat et al. 
The prevalence of alcohol and psychotropic drugs in fatalities of road-traffic accidents in Jordan during 2008-
2014. 
2016 
Jordan 
[54] Battah et al. Alcohol and psychoactive drugs in road traffic fatalities within northern district of Amman 2013 Jordan 
[56] Cheng et al. 
An epidemiological study on alcohol/drugs related fatal traffic crash cases of deceased drivers in Hong Kong 
between 1996 and 2000. 
2004 Hong Kong 
[57] Elliott et al. The prevalence of drugs and alcohol found in road traffic fatalities: a comparative study of victims. 2009 UK 
[58] Gjerde et al. Incidence of alcohol and drugs in fatally injured car drivers in Norway. 1993 Norway 
[59] Gjerde et al. Toxicological investigations of drivers killed in road traffic accidents in Norway during 2006-2008. 2011 
Norway 
[60] Hamnett et al. Toxicological findings in driver and motorcyclist fatalities in Scotland 2012-2015. 2017 Scotland 
[61] Jones et al. 
Five-year update on the occurrence of alcohol and other drugs in blood samples from drivers killed in road-
traffic crashes in Sweden. 
2009 
Sweden 
[62] Mercer et al. Alcohol, drugs, and impairment in fatal traffic accidents in British Columbia. 1995 Canada 
[63] Mravčík et al. Drugs and fatal traffic accidents in the Czech Republic. 2007 Czech Republic 
[64] Pelição et al Predominance of alcohol and illicit drugs among traffic accidents fatalities in an urban area of Brazil. 2016 Brazil 
[65] Terhune et al. The Incidence and Role of Drugs in Fatally Injured Drivers 1992 US 
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[66] Woodall et al Toxicological Findings in Fatal Motor Vehicle Collisions in Ontario, Canada: A One-Year Study 2015 Canada 
[67] Afzali et al. Frequency of alcohol and substance abuse observed in drivers killed in traffic accidents in Hamadan, Iran. 2013 Iran 
[68] Caplan et al. Drugs in Driver Fatalities: A preliminary study in the state of Maryland 1990 US 
[69] Cimbura et al. 
Incidence and Toxicological Aspects of Drugs Detected in 484 Fatally Injured Drivers and Pedestrians in 
Ontario 
1982 
Canada 
[70] Costa et al. 
Prevalence of ethanol and illicit drugs in road traffic accidents in the centre of Portugal: An eighteen-year 
update. 
2012 
Portugal 
[71] Crouch et al. The prevalence of drugs and alcohol in fatally injured truck drivers. 1993 US 
[72] Fortenberry et al. Analysis of drug involvement in traffic fatalities in Alabama 1986 US 
[73] Garriott et al. Incidence of drugs and alcohol in fatally injured motor vehicle drivers. 1977 US 
[74] Holmgren et al. Alcohol and drugs in drivers fatally injured in traffic accidents in Sweden during the years 2000-2002. 2004 Sweden 
[75] Logan et al. Drug and alcohol use in fatally injured drivers in Washington State. 1996 US 
[77] Sidlo J. Psychoactive substance-related deaths in road traffic accidents in Slovakia between 2000 and 2007. 2009 Slovakia 
[78] Turnbridge et al. The incidence of drugs in road accident fatalities in Great Britain 1990 UK 
[79]  Warren et al.   Drugs detected in fatally injured drivers in the province of Ontario 1981 Canada 
[80] Williams et al. Drugs in fatally injured young male drivers. 1985 US 
[81] Woodhouse et al. The Incidence of Drugs in Fatally Injured Drivers 1974 US 
[83] Seymour et al. 
Role of drugs and alcohol in impaired drivers and fatally injured drivers in the Strathclyde police region of 
Scotland, 1995-1998. 
1999 
UK 
[84] Carmen del Rio et al. Presence of illegal drugs in drivers involved in fatal road traffic accidents in Spain. 2000 Spain 
72 
Appendix F – Human Research Ethics Approval Letter 
Signature Removed
73 
 
Appendix G –Information Sheet for Participant Next-of-kin 
 
   
1 
INFORMATION SHEET FOR PARTICIPANTS’ NEXT-OF-KIN 
 
Research Project:  
Toxicological Findings in Fatal Road Traffic Accidents in Cape Town: A Pilot Study 
 
Supervisor: B. Davies | Co-supervisor: K. Auckloo | Researcher: N. Shongwe 
Division of Forensic Medicine and Toxicology, University of Cape Town 
 
Who are we? 
I, Nondumiso Shongwe, am an MPhil Biomedical Forensic Science candidate doing a research study with 
my supervisors on Road Traffic Accidents in Cape Town, South Africa. This information sheet will be used 
to interview and obtain consent from the family/relative/next-of-kin of the decedent involved in a road 
traffic accident and then admitted to the Salt River mortuary. 
 
What is the purpose of the study? 
Road Traffic Accidents (RTAs) are very common in South Africa and, unfortunately, often lead to the death 
of the individuals involved. One of the major contributors to fatal road accidents is the influence of alcohol 
and drugs (legal or illegal) on road users (e.g. drivers, passengers, pedestrians, motorcyclists and cyclists). 
There are limited to no information on substance use in RTAs in our country. However, the available 
information (especially from treatment centres) report that alcohol is the most commonly used substance 
followed by illegal drugs such as dagga, tik, heroin and cocaine. 
 
What is the study about? 
In this study, we will be testing for substances other than alcohol in biological samples (blood, urine, eye 
fluid and hair) collected during the routine autopsy of decedents due to fatal road accidents, which is a 
postmortem examination of all individuals who have passed away and are admitted to the Salt River 
mortuary. 
In a normal situation, when an individual is admitted to the Salt River mortuary following a death incident, 
the decedent’s family, relative or next-of-kin is called to identify the body of the individual. The informed 
consent interview typically occurs just before or after the body identification. Then, the collection of 
samples takes place during the routine scheduled postmortem examination of the decedent. The decedents 
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name and personal details will be removed from the information and samples collected for the study and 
no one will be able to identify them. 
After collection, the samples will be sent to the testing laboratory at the University of Cape Town Division 
of Clinical Pharmacology in Groote Schuur Hospital. The samples will be analyzed for substances and the 
results produced will remain confidential and will not be shared with anyone. These results will be stored 
in an access controlled database at University of Cape Town. 
Why are you being interviewed? 
You have been asked to be interviewed because you are presenting to the Salt River mortuary after your 
family member / next-of- kin / relative has passed away in a RTA, which is the topic of our study. We will 
be looking at which substances are more commonly found in road traffic fatalities within our communities 
and understand their role in road accidents. Please remember that the results are confidential and will not 
alter any criminal procedures or outcomes. Our findings will help in the intervention, management and 
prevention of road traffic accidents in Cape Town. 
 
Do you have to agree to the collection of samples? 
You are invited to give permission for the collection of samples from your family member, relative or next-
of-kin. Your contribution is completely voluntary and at no cost to you at all. You are free to not take part. 
Should you be willing to give consent, you will be asked to indicate this by signing a consent form. You 
may withdraw your consent from the study at any time, for any reason. Your decision on whether or not to 
give consent will not affect any services provided to you by the Forensic Pathology Services. 
 
What if you come to the mortuary much later? 
As mentioned earlier, the autopsy and collection of samples usually happen after obtaining consent and 
identifying the body. However, sometimes the scheduled autopsy procedure is performed before body 
identification and thus, the interview for obtaining consent is done after the samples have already been 
collected. In such cases, the samples will be collected and stored until such a time the delayed consent is 
obtained from the decedent’s next-of-kin / relative / family. In situations where obtaining delayed consent 
is unsuccessful, the respective samples will be destroyed. This will not affect the results of the autopsy 
procedure. Once again, your help is completely voluntary and you are free to refuse.  
 
What happens to the results? 
The results of this study will only be available to the researchers and the doctor who performed the autopsy. 
Specific results will not be provided to the family, relative or next-of-kin. At completion, the overall 
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findings may be published in a research journal and/or presented at meetings/conference, however, 
confidential information will not be shared in any capacity and no one will be able to link the results to the 
decedents. 
 
How will samples be stored and used in future studies? 
During the study period, biological samples will be stored according to the UCT Division of Medicine and 
Forensic Toxicology’s standard operating procedures for biological sample storage.  
Future research can be understood as one or more studies of possible future events and/or circumstances. 
The findings of this study may create new questions or ideas that should be investigated to contribute to the 
knowledge gap in forensic toxicology. For example, looking at a specific drug, specimen comparisons, and 
different instrumental analyses, among others.  
Given that this study forms part of the basis for future research in post mortem forensic toxicology in South 
Africa, samples collected from decedents in which consent is obtained for ‘storage of samples for future 
research’ will be transferred after the study period and stored in the Forensic Toxicology Unit laboratory at 
the University of Cape Town according to their standard sample long-term storage protocol. Where consent 
was not obtained, the samples will be destroyed after completion of the study. 
Ethical Approval? 
The research study was reviewed and approved by the University of Cape Town, Faculty of Health 
Sciences, Human Research Ethics Committee. This committee is responsible for protecting the rights of 
individuals who volunteer for participation in research studies.   
 
If you agree to take part, and have any further queries about the study please contact: 
 
Supervisor: Bronwen Davies | Tel: 021 406 6026 | Email: bronwen.davies@uct.ac.za 
 
Co-supervisor: Kathrina Auckloo | Cell: 072 642 1245 | Email: ackmar005@myuct.ac.za 
 
Researcher: Nondumiso Shongwe |Cell: 073 709 2663 | Email: SHNNON012@myuct.ac.za 
                   Human Research Ethics Committee | Tel: 021 406 6492 | Email: sumaya.ariefdien@uct.ac.za 
 
If you agree to participate in this study, please read and sign the consent form attached.
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Appendix H – Consent Form 
 
 
   
CONSENT FORM 
I, _______________________________________________________________ (full name of next-of-
kin), the spouse/partner/major child/parent/guardian/major brother/major sister (circle relationship) of the 
deceased with case number WC11/_________/_______, 
 
I confirm that:                 Yes        No  
      
1. I have read and understood the information provided on  
      the information sheet         
2. I understand that participation is voluntary        
3. I am aware that I may withdraw from the study at any time  
without reason or consequence whether before or during the study 
4. Anonymity will be maintained and neither the deceased  
or my family will be identified       
I consent to: 
1. The collection of biological samples and their toxicological analyses 
  for the presence and quantification of drugs       
2. Samples being stored for future use and  
3. Samples being used for future research with ethical approval from  
appropriate ethics committee  
 
____________________________________                 _______________________ 
Signature of next of kin                  Date 
____________________________________________________________________ 
Full Name of person obtaining consent 
___________________________________                      ______________________ 
Signature of person obtaining consent                                             Date 
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Appendix I – Toxicological analysis results for 30 case study cohort 
 
Case 
number 
Age Sex Road User Cause of Death 
Samples 
collected 
Samples in which 
drugs were detected 
Results 
001 37 Male Passenger Multiple blunt force injuries Blood, urine, VH None Negative 
002 39 Male Pedestrian Blunt force neck trauma Blood, urine, VH 
All collected samples 
 
9-Hydroxyrisperidone, Chinine, Methaqualone, Quinine 
003 45 Male Pedestrian 
Blunt force injuries to head and 
chest 
Blood, VH All collected samples Methaqualone 
004 51 Male Motorcyclist Multiple blunt force trauma Bile, VH All collected samples 
Acetaminophen, Ketamine, Lidocaine, Norketamine, 
Tranexamic acid, Warfarin, Chlorpheniramine, Morphine, 
Hydromorphone 
005 40 Male Cyclist 
Blunt force injuries to head and 
chest 
Blood, VH, urine Urine Hydromorphone, Morphine 
006 52 Male Driver Multiple blunt force injuries Blood, VH, urine All collected samples Diphenhydramine, Orphenadrine 
007 54 Male Passenger Blunt force chest trauma Blood, bile, VH None Negative 
008 19 Male Driver Multiple blunt force injuries Blood, VH, urine All collected samples Chlorpheniramine, Codeine, Diphenhydramine 
009 25 Male Motorcyclist Blunt force head injury Blood, urine, VH None Negative 
010 45 Male Pedestrian Blunt force head and chest injury Blood, urine, VH All collected samples Amitriptyline, Caffeine, Nicotinamide, Cotinine and Nicotine    
011 30 Male Pedestrian Multiple blunt force injuries Blood, bile, VH All collected samples Caffeine, Nicotinamide       
012 45 Male Passenger Blunt force chest trauma Blood Blood Caffeine, Cotinine         
013 29 Male Pedestrian Blunt force head trauma Blood Blood Caffeine, Cotinine, Nicotinamide 
014 43 Female Driver Multiple blunt force injuries Blood, VH All collected samples Caffeine, Chlorpheniramine    
015 26 Male Driver Head injury Blood, VH, urine All collected samples Acetaminophen, Caffeine, Cotinine, Nicotinamide, Nicotine    
016 34 Male Motorcyclist Multiple blunt force injuries Blood, VH, urine All collected samples Caffeine, Gliclazide, Nicotinamide 
017 33 Male Motorcyclist Blunt force head injury Blood, VH, bile All collected samples Caffeine, Nicotinamide         
018 35 Male Pedestrian Multiple blunt force injuries Blood, bile All collected samples 
Amphetamine, Caffeine, Nicotinamide, Caffeine, Cotinine, 
Diphenhydramine, Methamphetamine, Methaqualone, Nicotine   
019 43 Female Passenger Blunt force head trauma Blood Blood Acetaminophen, Caffeine, Chlorpheniramine, Nicotinamide 
020 62 Female Passenger Multiple blunt force injuries Blood Blood Acetominophen, Caffeine, Lidocaine 
021 36 Male Pedestrian Multiple blunt force injuries Blood, VH, urine All collected samples Caffeine, Cotinine, Nicotinamide, Nicotine 
022 26 Male Motorcyclist 
Blunt force injuries to chest and 
abdomen 
Blood, VH, bile All collected samples Caffeine, Cotinine, Nicotinamide, Nicotine Theophylline 
023 80 Male Pedestrian Multiple blunt force injuries Blood, VH, bile All collected samples Caffeine, Cotinine, Nicotinamide, Gliclazide 
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024 27 Male Pedestrian 
Blunt force injuries to chest and 
abdomen 
Blood, VH, bile All collected samples Cotinine, Nicotinamide 
025 53 Male Passenger Blunt force head trauma Blood, VH, bile All collected samples Acetaminophen, Caffeine, Nicotinamide 
026 45 Male Motorcyclist Multiple blunt force injuries Blood, VH, bile All collected samples Caffeine, Cotinine, Nicotinamide, Zopiclone 
027 39 Male Driver Consistent with traumatic asphyxia Blood, VH, bile All collected samples Caffeine, Nicotinamide 
028 42 Male Driver 
Multiple blunt force injuries to 
body 
Blood, VH, urine All collected samples Caffeine, Ketamine, Nicotinamide 
029 28 Male Passenger Blunt force head injury Blood, VH, urine All collected samples Caffeine, Codeine glucuronide 
030 37 Male Pedestrian 
Blunt force head and pelvic 
injuries 
Blood, VH, bile All collected samples Caffeine, Methamphetamine, Quinidine, Quinine 
 
